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1. Summary 
 
Glioblastoma multiforme (GBM) is the most common tumour of the central nervous 
system. Despite some progress in the therapy of the disease, patients still have a 
poor prognosis and a median survival of approximately 15 months. The biggest 
obstacle for successful surgical removal of glioblastoma is the high infiltration of 
invasive cancer cells throughout the brain. This makes it impossible to remove the 
complete tumour tissue, eventually resulting in relapse. Recent evidence suggests 
that glial-to-mesenchymal transition (GMT), a cellular program comparable to 
epithelial-to-mesenchymal transition (EMT), could play a major role in controlling the 
invasiveness of glioma cells. The transcription factors Snail and Slug are known to be 
major regulators of EMT in epithelial cancers. We therefore hypothesized that they 
may act as key components of GMT in glioma. Analysis of the expression of Snail 
and Slug in GBMs of different molecular subclasses revealed that these two EMT 
regulators are mainly expressed in the mesenchymal GBM subclass. By profiling a 
panel of signature markers we demonstrate that the combined loss of Snail and Slug 
impaired the TGFβ1-induced transition from a glial/proneural phenotype to a 
mesenchymal phenotype in GBM cells. Furthermore, we show that Snail and Slug 
play a crucial role in controlling glioblastoma stem cell properties, such as self-
renewal and the expression of cancer stem cell markers. In line with their role in 
GMT, Snail and Slug silencing led to a severely impaired invasive behaviour of GBM 
cells in vitro. Importantly, we found that Snail and Slug silenced GBM cells showed 
significantly reduced tumour growth in an orthotopic mouse xenograft model. Detailed 
analysis revealed that the reduced growth did not result from changes in proliferation 
and apoptosis due to the silencing of Snail and Slug. Instead, the invasiveness of 
Snail and Slug silenced cells was drastically reduced. In summary, this work 
demonstrates that Snail and Slug are major regulators of GMT in glioma, controlling 
the transition from a glial/proneural to a mesenchymal phenotype. Importantly, the 
mesenchymal phenotype is closely connected to the adoption of invasive and stem 
cell properties indicating that these are the major mechanisms through which Snail 
and Slug regulate GBM growth. This improved understanding of GMT in glioma could 
help to optimize existing GBM treatments and provide a basis for the development of 
novel therapeutic strategies.  
Zusammenfassung 
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2. Zusammenfassung 
 
Glioblastoma multiforme (GBM) ist der häufigste Tumor des zentralen 
Nervensystems. Trotz großer Fortschritte in der Therapie der Erkrankung haben 
Patienten immer noch eine schlechte Prognose und eine mittlere Lebenserwartung 
von 15 Monaten. Das größte Hindernis bei der chirurgischen Entfernung des Tumors 
ist die hohe Infiltration des Gehirns durch invasive Krebszellen. Dadurch ist es 
nahezu unmöglich das vollständige Tumorgewebe zu entfernen und viele Patienten 
leiden unter einem Rezidiv. Neueste Erkenntnisse legen nahe, dass gliale zu 
mesenchymale Transition (GMT), ein zelluläres Programm vergleichbar mit 
epithelialer zu mesenchymaler Transition (EMT), eine wichtige Rolle bei der Kontrolle 
der Invasivität von Gliomzellen spielt. Es ist bekannt, dass die Transkriptionsfaktoren 
Snail und Slug EMT-Hauptregulatoren in epithelialen Tumoren sind. Daher nehmen 
wir an, dass diese Transkriptionsfaktoren ebenfalls Schlüsselkomponenten von GMT 
in GBM sind. Eine Analyse der Expression von Snail und Slug in GBMs in 
verschiedenen molekularen Unterklassen zeigte, dass diese beiden Regulatoren vor 
allem in der mesenchymalen GBM-Unterklasse exprimiert werden. Wir zeigen 
anhand der Expression einiger Signaturmarker, dass der gleichzeitige Verlust von 
Snail und Slug den TGFβ1-induzierten Übergang von einem glialen/proneuralen 
Phänotypen hin zu einem mesenchymalen Phänotypen verhindert. Darüber hinaus 
demonstrieren wir, dass Snail und Slug eine entscheidende Rolle bei der Kontrolle 
der Glioblastom-Stammzelleigenschaften wie Selbsterneuerung und der Expression 
von Krebsstammzellmarker spielen. Der Verlust von Snail und Slug führte des 
Weiteren zu einer starken Beeinträchtigung des invasiven Verhaltens der Krebszellen 
in vitro. Wichtig ist, dass reduzierte Snail und Slug Expression in GBM Zellen zu 
einem signifikant reduzierten Tumorwachstum in einem orthotopischen Maus-
Xenograft-Modell führte. Detaillierte Analyse der Tumore zeigte, dass das reduzierte 
Wachstum nicht von Veränderungen der Proliferation und Apoptose der Zellen 
herrührte. Stattdessen konnten wir durch eine in vivo Invasionanalyse belegen, dass 
der Verlust von Snail und Slug die Invasionsfähigkeit der Zellen signifikant verringert. 
Zusammenfassend zeigt diese Arbeit, dass Snail und Slug wichtige GMT-
Regulatoren sind die den Übergang von einem glialen/proneuralen zu einem 
mesenchymalen Phänotypen kontrollieren. Wichtig ist, dass der mesenchymale 
Zusammenfassung 
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Phänotyp sehr eng mit der Invasivität und dem Erwerb von Stammzell-Eigenschaften 
der Gliomzellen verknüpft ist. Das legt nahe, dass dies wichtige Mechanismen sind 
durch die Snail und Slug das Tumorwachstum von GBM kontrollieren. Dieses 
verbesserte Verständnis von GMT könnte dazu beitragen bestehende 
Behandlungsformen von GBM zu verbessern und neue therapeutische Ansätze zu 
finden. 
 
 
Introduction 
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 3. Introduction 
 
Primary tumours of the central nervous system consist of a quite heterogeneous 
group of benign and malignant neoplasias (Soeda et al.). The majority of CNS 
tumours are of glial origin and termed glioma (Ohgaki and Kleihues, 2005). Initially 
glioma were classified according to the original glial cell type that the tumour arose 
from: astrocytic, oligodendrocytic, ependymal or mixed forms (Louis et al., 2007). 
However, recent evidences obtained from human and animal studies also suggest 
neural stem cells as alternative cells of origin of gliomas (Canoll and Goldman, 2008; 
Caussinus and Gonzalez, 2005; Dirks, 2006; Galli et al., 2004; Singh et al., 2003). 
Glioblastoma multiforme belongs to the most common glial neoplasia and shows the 
highest malignancy and aggressiveness in the group of gliomas. Patients diagnosed 
with GBM have a median survival of fifteen months (Norden and Wen, 2006). In the 
last years research improved the therapeutic approaches to treat the patients, but the 
prognosis is still poor. The most common therapy is the surgical removal of the 
primary tumour combined with radio-and or chemotherapy. Unfortunately it is nearly 
impossible to remove and eliminate all cancer cells, primarily due to the high invasive 
capacity of the tumour cells into the surrounding brain parenchyma already prior to 
the surgery. Secondary tumours arise from these remaining and invading cells and 
reduce the survival of the patients. 
 
3.1 Classification of malignant glioma 
 
The World Health Organization (WHO) classified gliomas in terms of malignancy into 
grade I, II, III and IV (published in the 3rd edition by Kleihues and Cavenee in 2000, 
complemented by Louis and Kleihues in 2007, Table 3.1). These grades are based 
on histological facts like cell differentiation, cell and cell core polymorphism, cell 
density, proliferation rate, proliferation of endothelium and tumour necrosis.  
Tumours classified as grade I glioma, such as pilocytic astrocytoma and 
subependymal giant cell astrocytoma, show a high extent of differentiation and a slow 
proliferation with a good survival prognosis for the patient.  
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Grade II gliomas, such as diffuse astrocytoma, pleomorphic xanthoastrocytoma or 
pilomyxoid astrocytoma, are characterized by diffuse infiltration of the brain 
parenchyma, weak proliferation and patients often suffer from relapse of the tumour. 
The median survival of patients with grade II tumours is between three to eight years.  
Anaplastic astrocytoma and anaplastic oligodendroglioma are examples for grade III 
tumours. Characteristics for this tumour type are atypical cell core morphology, high 
rate of proliferation and single cell necrosis. Patients have a median survival of two to 
three years (Norden and Wen, 2006).  
Grade IV tumours show high proliferation, necrotic areas, hyper proliferating 
endothelium and high polymorphism. Glioblastoma multiforme (GBM) is the most 
abundant tumour type in this class. Patients diagnosed with GBM have a median 
survival of fifteen months. The median age of patients diagnosed with glioblastoma is 
64 years. 
WHO-Grade Tumour Type 
I Pilocytic astrocytoma, subependymal 
giant cell astrocytoma 
II diffuse astrocytoma, pleomorphic 
xanthoastrocytoma, pilomyxoid 
astrocytoma 
III Anaplastic astrocytoma, anaplastic 
oligodendroglioma,  
IV Glioblastoma 
Table 3.1 Examples of grade I-IV gliomas, based on the WHO classification of tumours 
of the central nervous system (Louis et al., 2007) 
Nearly 70% of all diagnosed primary malignant brain tumours in the USA are 
gliomas. Every year more than 14.000 new cases are reported. That means that 5 
people out of 100.000 are diagnosed with glioma. Approximately 60 to 70% of 
malignant gliomas are glioblastoma, 10 to 15% are anaplastic astrocytoma, 
anaplastic oligodendroglioma and anaplastic oligoastrocytoma account for 10%. The 
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rest are the less common anaplastic ependymoma and anaplastic ganglioglioma 
(Wen and Kesari, 2008) 
 
3.1.1 Molecular subclasses of glioma 
 
With the development of new molecular techniques the classification of gliomas was 
refined to include information related to the expression of specific genetic signatures. 
With the help of microarray gene expression profiling it was possible to identify 
molecular subtypes of gliomas as well as genes associated with tumour grade, 
progression, and patient survival (Godard et al., 2003; Rickman et al., 2001; van den 
Boom et al., 2003). While GBM and anaplastic astrocytomas are still defined by 
histological criteria, several reports showed that expression profiles predict patient 
outcome better than a histological examination (Freije et al., 2004; Nutt et al., 2003). 
This led to the hypothesis that neoplasms defined morphologically as anaplastic 
astrocytoma and GBM could represent a mix of molecular genetic subtypes. 
In 2006 Phillips et al. (Phillips et al., 2006) showed prognostically relevant molecular 
subclasses of high grade glioma, especially high grade astrocytoma. These 
subclasses resemble known stages in neurogenesis. They divided their expression 
profiling in three subgroups: proneural, proliferative and mesenchymal. 
The proneural subclass showed a better prognosis in patient outcome and expressed 
genes that are associated with normal brain and the process of neurogenesis (for 
example Olig2 (oligodendroglial marker 2) and MAP2 (microtubule associated protein 
2)). For the proliferative subclass the authors reported increased expression of genes 
involved in cell proliferation (for example PCNA (proliferating cell nuclear antigen) 
and TOP2A (topoisomerase II alpha). The mesenchymal subclass was defined by the 
enrichment of cells of mesenchymal origin with the upregulation of respective genes 
like CD44 (transmembrane glycoprotein) or YKL40 (human chitinase 3 like protein 1) 
as well as the stem cell marker CD133 (transmembrane glycoprotein). Both classes 
showed a poor overall survival of the patients. Interestingly recurrent tumours were 
observed to shift in their expression profile to the mesenchymal subclass. 
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Based on the study described above and on data from The Cancer Genome Atlas 
(TCGA) glioblastoma cohort in 2010 Verhaak et al. (Verhaak et al., 2010) defined 
four subclasses of tumours (proneural, neural, classical, mesenchymal) all 
morphologically diagnosed as GBM.  
The proneural subtype showed an amplification of PDGFRA (platelet derived growth 
factor receptor A) and very frequently a point mutation in IDH1 (isocitrate 
dehydrogenase 1) as well as a mutation and the loss of heterozygosity in p53. 
Furthermore a high expression of oligodendrocytic development genes such as 
PDGFRA and Olig2 was characteristic for this subclass. 
In accordance to the study of Phillips et al. the expression of YKL40 and CD44 was 
elevated in the mesenchymal subclass. Furthermore they found a frequent 
hemizygous deletion of NF1 and a co-occurring mutation of NF1 (neurofibromin 1) 
and PTEN (phosphatase and tensin homologue). Components of the TNFα and the 
NF-κB pathways were highly upregulated as a consequence of higher necrosis and 
associated inflammatory infiltrates in the mesenchymal class. 
The neural subclass was difficult to distinguish from normal brain because of the high 
expression of neuron markers like NEFL (neurofilament), GABRA1 (gamma-
aminobutyric acid (GABA) A receptor alpha 1), SYT1 (synaptotagmin I) and SLC12A5 
(potassium/chloride transporter), but all samples were histologically identified as 
GBM. 
The classical subtype showed an amplification of chromosome 7 and a loss of 
chromosome 10, no mutations in p53 and amplification and a high mutation rate of 
EGFR (epidermal growth factor receptor). Co-occurring with the amplification of 
EGFR was a homozygous deletion of CDKN2A (cyclin-dependent kinase inhibitor 
2A). In this subclass a high expression of neural precursor and stem cell marker 
nestin was found, as well as a high activation of the Notch and sonic hedgehog 
pathways. 
Shortly after the analysis by Verhaak et al. another possibility to get a deeper insight 
in the molecular differences of GBM was published. The method of choice was to 
identify promoter DNA methylation alterations of 272 GBM tumours in the TCGA 
cohort (Noushmehr et al., 2010). It was found that a distinct subset of samples 
displays a concerted hypermethylation at a large number of loci. This could indicate 
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the existence of a glioma CpG-island methylator phenotype (G-CIMP), as previously 
described for colorectal cancer (Toyota et al., 1999). G-CIMP tumours belong to the 
proneural subgroup and are more prevalent in lower-grade glioma. Interestingly, the 
G-CIMP phenotype seems to be tightly associated with IDH1 mutations. Patients with 
G-CIMP tumours are younger at the time of diagnosis and have an improved 
outcome. 
 
3.2 Invasion and migration of tumour cells 
 
One of the main characteristics of GBM is the high invasive and migratory capacity of 
tumour cells. Single cells or groups of cells are able to leave the primary tumour 
mass and invade along the white matter, myelinated fibres or along blood vessels in 
the surrounding brain parenchyma even until the contralateral hemisphere where 
they are the basis for recurrent tumours. Recurrence is usually still observed even 
after surgical removal of the primary tumour and chemo- or radiotherapy. The 
infiltrating tumour micro-satellites or small groups of cells are hard to visualize and to 
discriminate from healthy brain tissue during surgery or in MRI (Black, 1997; Claes et 
al., 2007; Giese and Westphal, 1996; Louis et al., 2007).  
The very common necrotic areas in glioblastoma are often surrounded by 
pseudopalisades with a higher cell density. These pseudopalisades consist of cells 
which show low proliferation and a higher apoptosis rate than cells that are not in 
close proximity to necrotic areas. The reason for this higher cell density in 
perinecrotic areas seems to be an enhanced migration of tumour cells out of the 
necrotic tissue. These migratory cells are believed to be selected for a more 
aggressive, more malignant and more resistant phenotype (Brat et al., 2004; Claes et 
al., 2007). 
Despite the high invasiveness of glioma cells distant metastasis outside neural 
tissues is observed very rarely (Subramanian et al., 2002). The reasons for that are 
still not fully understood. Possible contributing factors could be the blood-brain barrier 
which prevents the cells to leave the brain, the lack of lymphatic drainage or the 
special microenvironment of the brain which is not found in other organs and makes it 
Introduction 
 
9 
 
more difficult for cancer cells from the brain to adapt in distant organs and establish 
metastasis. 
 
3.2.1 Mechanisms of invasion and migration 
 
 
Fig. 3.2 Schematic illustration of the principal mechanisms of glioma invasion. 
Principally, glioma invasion can be divided into 4 steps: 1. Detachment from the tumour 
mass. 2. Attachment to the ECM. 3. Degradation of the ECM and 4. Migration to a distant 
side. The involved signalling pathways and cellular components are described in the text. 
(Image taken from Nakada, 2007) 
 
The molecular principles of tumour cell invasion are based on changes in the 
mechanisms of cell adhesion to the extracellular matrix (ECM) components and loss 
of direct cell-cell contact. For the detachment of tumour cells from the main tumour 
mass cell adhesion proteins have to be cleaved or their expression has to change 
(Nakada et al., 2007). A good example for cleavage of adhesion molecules in GBM is 
the transmembrane glycoprotein CD44. It interacts with hyaluronic acid in the ECM 
and gets cleaved by proteinases ADAM10 and 17 (Nagano et al., 2004; Okamoto et 
al., 1999) (Fig. 3.2). During the loss of cell adhesion especially in GBM the 
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expression of the neural cell adhesion molecule NCAM is also reduced (Sasaki et al., 
1998). Furthermore calcium depending adhesion molecules like cadherins (N-
cadherin and E-cadherin) are changed in their expression during the process of 
invasion. A reduced E-cadherin expression and an induced expression of N-cadherin 
are important for the cell motility and migration (Cavallaro and Christofori, 2004; 
Thiery, 2003). The particular role of these two proteins in invasiveness of tumour 
cells will be elaborated later in detail in context of epithelial-to-mesenchymal 
transition (see section 3.3).  
In the brain the ECM works as a scaffold to guide invasive cells. To make way for the 
migrating tumour cells the ECM gets degraded by proteolytic proteins. In glioma it is 
known that especially the proteinases MMP-2 and -9 (matrix metalloproteinases), 
ADAM10, 12m and 17, the serine proteinase uPA (urokinase-type plasminogen 
activator) and its receptor uPAR as well as cysteine proteinases (cathepsin B, L, S) 
play an important role during the degradation of the ECM (Nakada et al., 2007) (Fig. 
3.2). 
The motility of the cells depends furthermore on many more paracrine and autocrine 
signalling pathways. Through several signalling molecules the cell morphology 
changes, the cell gets polarized and starts to form protrusions like pseudopodia, 
lamellipodia and filopodia to be able to invade and migrate. Invasive glioma cells 
show an upregulation of Tenascin-C which stimulates via the RhoA signalling 
pathway the development of actin-rich filopodia (Mahesparan et al., 2003; Wenk et 
al., 2000). Also the interaction of ECM components like fibronectin, collagen, laminin 
and vitronectin with the intracellular actin-cytoskeleton via integrins is an important 
requirement for cell motility. In invasive glioma cells it was observed that especially 
integrin-β1 is upregulated (Hynes, 2002; Perego et al., 2002) (Fig. 3.2).  
The final step in the mechanism of migration is the formation of membrane anchors 
which enables the cell to move forward through contractions of the cytoskeleton 
(Nakada et al., 2007) (Demuth and Berens, 2004) (Fig. 3.2).  
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3.3 Epithelial-to-mesenchymal transition 
  
During tumour development from a benign to a malignant or metastatic tumour the 
tumour cells have to undergo morphological and phenotypical changes. In case of 
epithelial cancer types the cells develop from highly differentiated epithelial cells to 
less differentiated, migratory and invasive cells with a mesenchymal phenotype. This 
specific change is called epithelial-to-mesenchymal-transition or shortly EMT. 
Originally this transition program is known from embryonic development. It is very 
important for the positioning and differentiation of particular cell types and for the 
development of complex structures of many tissues and inner organs during 
gastrulation and the formation of the neural crest (Thiery, 2003). 
An epithelial cell layer is characterised by close cell-cell contacts between 
neighbouring cells through adherens junctions, tight junctions and desmosomes. 
During EMT these close connections are abrogated to enable the detachment of the 
cells from the basal membrane and to leave the cell layer due to a higher motility 
(Fig. 3.3). For that a morphological change of the cells is necessary and the 
cytoskeleton gets rearranged. Epithelial cells have a rounder shape than 
mesenchymal cells which show a more spindle-shaped structure and more 
protrusions like filopodia which are typical for migratory and invasive cells. 
During tumorigenesis, epithelial cancer cells are also capable of undergoing changes 
analogous to EMT, including the hallmarks of EMT: repression of epithelial specific 
proteins like E-cadherin and upregulation of mesenchymal proteins like N-cadherin, 
vimentin and fibronectin (Peinado et al., 2007; Thiery, 2002; Yilmaz and Christofori, 
2009). The loss of E-cadherin is one of the key events during EMT and can be 
correlated with increased tumour progression and metastatic incidence in carcinoma 
(Birchmeier and Behrens, 1994; Perl et al., 1998). In tumour cells E-cadherin is 
transcriptionally repressed by a group of EMT repressor genes. These repressor 
genes are mainly Zinc-finger transcription factors of the Snail-family (SNAI1 (Snail), 
SNAI2 (Slug)) (Batlle et al., 2000; Bolos et al., 2003; Cano et al., 2000), and the ZEB-
family (ZEB1, ZEB2) (Comijn et al., 2001; Eger A et al., 2005; Peinado et al., 2007) 
(Fig. 3.3). All these transcription factors bind the E-box consensus sequence 
CANNT(G) in the promoter region of E-cadherin and repress the transcription of the 
gene (Batlle et al., 2000; Cano et al., 2000). SNAI1/2 and ZEB1/2 are also involved in 
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the epigenetic regulation of E-cadherin by recruiting chromatin-remodelling 
complexes (HDAC2 complex) to the E-cadherin gene (Peinado et al., 2004; Peinado 
et al., 2007) 
 
 
Fig. 3.3 Schematic illustration of EMT. Due to microenvironmental triggers like hypoxia or 
TGFβ signalling transcriptional inducers like Snail and Slug get activated and the expression 
of E-cadherin is repressed. The cells lose tight cell-cell contact and start to leave the 
epithelial cell layer. Subsequently, the expression of mesenchymal markers like vimentin and 
N-cadherin is elevated. Cells which gain a mesenchymal phenotype start to migrate and 
invade. Furthermore, EMT can promote the acquisition of a cancer stem cell phenotype. 
Adapted from (Pouyssegur et al., 2006). 
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Several signalling pathways involved in tumour cell migration or cell 
growth/proliferation are in turn influenced by the loss of E-cadherin, for example the 
canonical Wnt pathway and the remodelling of the actin-cytoskeleton by Rho-family 
GTPase dependent pathways (Cavallaro and Christofori, 2004; Perego et al., 2002).  
Many EMT repressors are mainly expressed at the invasive front of tumours but also 
in necrotic/hypoxic areas and are known to be regulated by many pro-tumorigenic 
pathways like HIF, TGFβ, STAT3, NF-κB  as well as by other autocrine growth 
factors like HGF, EGF or FGF (Janda et al., 2002; Kang and Massague, 2004; Lu et 
al., 2003; Peinado et al., 2003; Spaderna et al., 2006; Thiery et al., 2009; Yook et al., 
2005). These growth factors are either produced by the tumour cells themselves or 
by the neighbouring stromal cells. TGFβ is also known as the most potent inducer of 
SNAI transcription, discussed below (see section 3.3.3). 
There is growing evidence that a program comparable to EMT can also be observed 
in non-epithelial cancers like gliomas. In this context it can rather be termed GMT 
(glial to mesenchymal transition) due to distinctive features of glial cells, as compared 
to epithelial ones. Interestingly the same repressive transcription factors and 
pathways could play an important role in glioma as well, but so far there is only little 
known. Previous studies gave some of the first evidence that the EMT factors Snail 
and Slug are very important regulators of this transitions (see section 3.3.2 and 
3.3.3). But also other EMT regulators like TWIST1 and ZEB1 can play a functional 
role in GBM growth, invasion and therapy resistance related to a transition to a 
mesenchymal phenotype (Siebzehnrubl et al., 2013) (Mikheeva et al., 2010) 
 
3.3.1 Induction of EMT by Hypoxia   
 
Cellular responses to low oxygen tension (hypoxia) are mediated by the hypoxia 
inducible factors (HIF). Under hypoxic conditions the HIFα subunit (HIF1α or HIF2α) 
gets stabilised and interacts with the HIFβ subunit to form a heterodimer. 
Subsequently the HIF dimer binds to hypoxic responsive elements (HREs) in the 
promoter regions of hypoxia regulated genes to induce their expression. Normoxic 
conditions lead to the proteasomal degradation of HIFα through ubiquitination by VHL 
(von Hippel-Lindau) and no expression of hypoxia responsive genes. 
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Hypoxia is reported as a potent inducer of EMT by elevating the expression of the 
respective transcriptional regulators. The importance of HIF to induce EMT in 
epithelial cancers is reported for pancreatic ductal adenocarcinoma (Liu et al., 
2014a), hepatocellular carcinoma (Liu et al., 2014b), ovarian carcinoma (Du et al., 
2014) and lung cancer (Shaikh et al., 2012). In non-epithelial cancers like GBM it is 
reported that tumours with a mesenchymal gene signature show a high level of 
necrotic/hypoxic areas (Verhaak, 2010). Furthermore it is known that cells 
surrounding such necrotic zones (pseudopalisading cells) and therefore lacking a 
sufficient oxygen supply show a high expression of the mesenchymal transcription 
factors C/EBP-β and C/EBP-δ together with a poor prognosis for patients with this 
class of tumours (Cooper et al., 2012). In this context a recent study reported that in 
necrotic/hypoxic areas EMT is mainly promoted by the hypoxic induction of the EMT 
regulator ZEB1 which facilitates the expression of mesenchymal markers and 
impacts the invasiveness of the cancer cells (Joseph et al., 2015). 
 
3.3.2 Induction of EMT by TGFβ 
 
TGFβ is, like hypoxia, a master inducer of mesenchymal transition and invasion of 
cancer cells. Latent TGFβ is immobilized to the ECM through its components 
fibronectin and fibrillin by interaction with latent TGFβ-binding proteins (LTBP) like 
LTB1-4. To activate TGFβ, it needs to be released by limited proteolysis mediated by 
MMPs or furins which are activated and released by activated stromal cells (Mu et al., 
2002). As an alternative way to make ECM bound TGFβ accessible for its receptors 
is that integrins bind to latent TGFβ-binding protein complexes and pull to induce a 
conformational change (Wipff et al., 2007). Also TNFα can upregulate the 
transcription of TGFβ (Sullivan et al., 2009) and subsequently accelerate TGFβ-
induced EMT dramatically (Bates and Mercurio, 2003). 
Nevertheless, TGFβ has a dual role in carcinogenesis. In early lesions it is 
considered to be a master anti-inflammatory cytokine which prevents uncontrolled 
proliferation of the cells (Siegel and Massague, 2003). But many more advanced 
tumours show a resistance towards the growth-inhibitory effects of TGFβ, instead it is 
able to act as an activator of prometastatic pathways like EMT (Jakowlew, 2006).  
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Taken together TGFβ can act on the one hand as a tumour suppressor at early 
stages of cancer progression but on the other hand contribute later to the malignant 
progression by promoting invasion and metastasis and help to induce oncogenic 
EMT (Massague, 2008) (Galliher et al., 2006).  
TGFβ induces EMT through two distinct pathways, the Smad-dependent pathways 
and the Smad-independent pathway (Kalluri and Weinberg, 2009). The Smad-
dependent pathway includes the binding of TGFβ by the TGFβ receptors type I and II 
which form tight complexes. The activation of the receptors lead to phosphorylation of 
Smad2 and Smad3 and the receptor-related Smad (R-Smad) proteins (Massague 
and Wotton, 2000). Phosphorylated Smads form heteromeric complexes with Smad4 
and translocate into the nucleus to regulate transcription of EMT associated target 
genes like Snail, Slug and ZEBs (Derynck and Zhang, 2003). The Smad independent 
pathway is characterised by the direct activation of several non-Smad signalling 
pathways through TGFβ including Ras/ERK, c-Jun and JNK (Myazono, 2009; 
Ozdamar et al., 2005).      
After single tumour cells or groups of cells leave the primary tumour mass and when 
the invading cells reached the surrounding tissue or their specific side of metastasis 
the EMT program is reversible. Through interaction with the new microenvironment 
the cells can turn back to their initial epithelial phenotype. This backwards conversion 
is called MET (mesenchymal to epithelial transition) (Spaderna et al., 2006; Thiery, 
2003; Thiery et al., 2009).  It seems that EMT in cancer is only transiently activated 
and may be locally limited to the invasive front and heavily regulated by complex 
orchestrated environmental cues.  
 
3.3.3 The Snail super-family of transcription factors and their role in E(G)MT 
 
Snail transcription factors were first discovered in the fruit fly Drosophila 
melanogaster. In this organism they are essential for the development of the 
mesoderm (Alberga et al., 1991; Grau et al., 1984). In vertebrates there are three 
Snail family members: Snail1 (Snail), Snail2 (Slug) and Snail3 (Smuc). Interestingly, 
in contrast to the other two Snail proteins, Snail3 is a non-essential protein in 
embryogenesis of mice which shows a tissue specific expression in thymus and 
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skeletal muscles (Bradley et al., 2013) and seems to have only poor abilities to 
induce EMT (Gras et al., 2014).                                                                     
Snail is a protein with a very short half-life. Its turn-over in the nucleus is decreased 
but in the cytoplasm it gets rapidly degraded by proteasomes (Zhou et al., 2004). All 
members of this transcription factor family encode transcriptional repressors. They all 
share a highly conserved domain organisation. The C-terminal domain contains four 
to six C2H2 type zinc fingers and binds target gene promoters at the E-box consensus 
motif 5´-CANNTG-3´ and is responsible for the repressive activity of Snail (Nieto, 
2002). The N-terminus of all Snail members harbours the conserved SNAG domain. 
This domain is essential for the binding of co-repressor complexes to transcriptionally 
and epigenetically influence the expression of target genes. Such co-repressor 
complexes include the Sin3A, histone deacetylase 1/2 (HDAC1/2) complex (Peinado 
et al., 2004), the Polycomb repressive complex 2 (PRC2) (Herranz et al., 2008), the 
protein arginine methyltransferase 5 (PRMT5)/Ajuba complex (Hou et al., 2008) or 
the lysine-specific demethylase 1 (LSD1)/coREST complex (Lin et al., 2010) (Fig. 
3.4). 
In the centre of the Snail proteins one can find a serine-rich domain (SRD) where 
most sites for post-translational modifications are located and a nuclear export 
sequence (NES), which are important for protein stabilisation, activation, localisation 
and degradation of the gene product (Dominguez et al., 2003). In the SRD many 
phosphorylation sites are found which get phosphorylated mainly through GSK3β but 
also PAK1 phosphorylates serine 246 and enhances the accumulation of Snail in the 
nucleus and promotes subsequently its repressive activity in the nucleus (Yang et al., 
2005) (Fig. 3.5). The small C-terminal domain phosphatase (SCP) removes such 
phosphorylations through interaction with Snail to stabilize the protein (Wu et al., 
2009b). Nevertheless, phosphorylated Snail interacts with β-TrCP and gets degraded 
subsequently (Zhou et al., 2004). Especially, the F-box E3 ubiquitin ligase FBXL14 
promotes the ubiquitination and proteasomal degradation of Snail. Furthermore lysyl 
oxidase-like 2 (LOXL2) binds to the SNAG domain of Snail and antagonises the 
interaction between Snail and β-TrCP or FBXL14, which leads to stabilisation of Snail 
(Vinas-Castells et al., 2010). Recently it was described in breast cancer that the E3 
ligase SCF-FBXO11 targets Snail for ubiquitination and degradation. The authors 
could show that the degradation of Snail by FBXO11 is dependent on Ser-11 
phosphorylation by protein kinase D1 (PKD1). This degradation process inhibits 
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Snail-induced EMT, tumour initiation and metastasis in various breast cancer models 
(Zheng et al., 2014). 
 
 
Fig. 3.4 Regulation of Snail expression. Summary of direct regulators of Snail and their 
interaction locations and respective pathways (Kaufhold and Bonavida, 2014). 
 
Snail expression or induction in cancer depends on many signalling molecules from 
the tumour microenvironment. Growth factors like HGF, FGF or EGF activate 
signalling through receptor tyrosine kinases (RTKs) via the RAS-MAPK or PI3K-Akt 
pathway which leads to an induction of Snail expression (Ciruna and Rossant, 2001; 
Lu et al., 2003). TGFβ and the SMAD pathway play an important role in inducing 
Snail expression, which in turn helps to overcome the tumour suppressing effects of 
TGFβ. Snail mediates resistance to TGFβ initiated apoptosis and shifts the response 
to promotion of tumour progression (Franco et al., 2010). TGFβ increases also Notch 
signalling via SMAD3 which leads to elevated expression of Jagged1 and HEY1 and 
subsequently promotes expression of Slug which leads to an EMT phenotype (Leong 
et al., 2007). But Notch also controls Snail expression via two synergistic 
mechanisms: direct transcriptional activation of Snail or a more indirect mechanism 
through lysyl oxidase (LOX). Under hypoxic conditions Notch recruits HIF1α to the 
promoter of LOX, which increases LOX expression, stabilises the Snail protein and 
leads to EMT (Grego-Bessa et al., 2004; Sahlgren et al., 2008). A very important 
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signalling pathway in tumour progression is the Wnt-pathway. Activation of this 
pathway inhibits GSK3β-mediated phosphorylation of β-catenin and Snail (two of its 
main targets) and stabilises the two proteins in the nucleus (Barrallo-Gimeno and 
Nieto, 2005; Kim et al., 2002; Liebner et al., 2004). 
Another important regulator of Snail expression is the NF-κB pathway. Snail gets 
regulated by this pathway transcriptional and post-translational. NF-κB binds to the 
human Snail promoter (at positions -194 and -78) (Fig.3.5) and elevates the 
expression of Snail (Barbera et al., 2004). The post-translational regulation of Snail 
works via activation of NF-κB through AKT signalling, which leads to phosphorylation 
of IKKα and the upregulation of Snail (Julien et al., 2007; Ozes et al., 1999; 
Romashkova and Makarov, 1999; Zhou et al., 2000).  
Inflammatory pathways also provide important microenvironmental cues during 
tumour progression. TNFα, a major inflammatory cytokine, stabilises functional Snail. 
By disrupting the binding of Snail with GSK3β and β-TrCP, TNFα inhibits the 
phosphorylation and ubiquitination of Snail (Fig. 3.6) (Wu et al., 2009a).   
In addition to the microenvironmental associated pathways Snail and Slug are also 
able to autoregulate their own expression. Both bind to the own promoter and 
repress their expression through an autoregulatory loop (Fig. 3.5) (Peiro et al., 2006). 
 
Fig. 3.5 Regulatory elements in the SNAI promoter. Overview showing different regulatory 
elements and the respective transcriptional regulators of the Snail promoter (Kaufhold and 
Bonavida, 2014). 
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Fig. 3.6 Localisation and stabilisation of Snail. Schematic overview of translational 
modifications changing the localisation and the stability of Snail (Kaufhold and Bonavida, 
2014). 
 
3.4 Cancer stem cells 
 
Since many years it is a main goal in cancer research to explain the origin of cancer 
and to use this knowledge for therapeutic approaches. It is known that cancer arises 
from a series of mutations in a few cells or even in a single cell which can be called 
founder cell. Such cells could gain unlimited and uncontrolled expansion potential 
and a long life-span (Hanahan and Weinberg, 2011). To explain these observations 
two hypothetical models are currently under discussion. The first is the stochastic 
model in which it is assumed that all cells of the tumour have the same tumorigenic 
potential and can account for tumour growth (Reya et al., 2001). The second one is 
the hierarchical model, according to which only a small subpopulation of tumour cells 
have the capacity to self-renew and maintain the tumour growth, while the bulk of the 
tumour cells are differentiating or terminally differentiated cells (Fig. 3.7) (Reya et al., 
2001; Visvader and Lindeman, 2008, 2012).    
The hierarchical model, also referred to as the cancer-stem-cell or the tumour- 
initiating-cell model, was described first in human myeloid leukaemia(Bonnet and 
Dick, 1997; Lapidot et al., 1994). Later the concept was extended to human solid 
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tumours like breast cancer(Al-Hajj et al., 2003; Cho et al., 2008; Ginestier et al., 
2007), prostate cancer (Collins et al., 2005) and brain tumours as well (Harris et al., 
2008; Singh et al., 2003; Son et al., 2009) 
 
Fig. 3.7 Schematic illustration of the cancer stem cell model. The tumour mass consists 
of three cell types with a different state of differentiation. A few cells in the tumour mass 
exhibit a high capacity of self-renewal and a very undifferentiated cell status. These tumour 
stem cells are able to give rise to more differentiated progenitor cells and to new stem cells 
(self-renewal). Progenitor cells can give rise to differentiated tumour cells, which form the 
main tumour cell population (modified from Till Acker).  
 
Cancer stem cells (CSC) are a small minority of tumour cells which show 
characteristics comparable to normal stem cells, such as differentiation potential and 
self-renewal. In addition, CSCs show a high resistance to chemo-and radiotherapy 
(Bao et al., 2006a). Another important fact in the context of normal stem cells and 
CSCs is the homeostatic control, the maintenance of the stem cell pool (Reya et al., 
2001; Sell, 2004, 2006; Sell and Pierce, 1994; Wicha et al., 2006). When stem cells 
divide they give rise to one daughter cell which remains in the stem cell state, 
whereas the other daughter cell can enter the process of differentiation (Fig. 3.7).  
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3.4.1 Cancer stem cells in glioma  
 
Within solid tumours gliomas were among the first tumour entities in which the CSC 
model was experimentally validated (Venere et al., 2011) 
Like in other cancer types several markers are used to identify and characterise brain 
tumour stem cells (BTSCs). One of the most prominent markers in brain tumour stem 
cells is the surface protein CD133. It was shown that FACS sorted CD133 positive 
cells can initiate new brain tumours when transplanted into the striatum of 
immunodeficient mice whereas CD133 negative cells were not able to form a tumour 
(Singh et al., 2003) (Galli et al., 2004; Singh et al., 2003). The obtained tumours 
showed the classic features of GBM like extensive migration and infiltration and also 
the histological features were comparable. It was also possible to re-isolate stem like 
cells from theses tumours and in a second transplantation experiment with these 
cells GBM tumours were obtained, demonstrating the self-renewal and tumour-
initiating ability of these cells in vivo. Other markers that are often used to identify 
BTSCs are integrinα6 (Lathia et al., 2010), CD15 (Son et al., 2009), EGFR (Jin et al., 
2011), A2B5 (Ogden et al., 2008), L1CAM (Bao et al., 2008), CD44 (Anido et al., 
2010) and the chemokine CXCR4 (Ping et al., 2011). Through a side-population 
approach further stem cell signature genes, ASPHD2 (aspartate beta-hydroxylase 
domain-containing protein 2), NFATc2 (nuclear factor of activated T cells 2, part of 
the calcineurin pathway) and MAML3 (mastermind-like protein 3, part of the Notch 
pathway) were identified. All these side population genes are hypoxia-inducible 
through the activation of HIF2α (Seidel et al., 2010).  
The regulation of brain tumour stem cells shows the same key mechanisms like 
normal neuronal progenitor cells, found in the subventricular zone (SVZ). Self-
renewal in adult neural stem cells relies predominantly on the Notch pathway (Hitoshi 
et al., 2002; Shen et al., 2004), overexpression of Notch receptors and their ligands 
Delta-like 1 and Jagged1 are correlated with proliferation of human glioma cells 
(Purow et al., 2005). Additionally, self-renewal in normal neural stem cells and 
tumorigenesis of the central nervous system is positively regulated through the 
repression of INK4a and the tumour suppressor ARF (Molofsky et al., 2003).  
Furthermore, the regulation and maintenance of neural stem cells, progenitor cells 
and cancer stem cells relies not only on specific intrinsic genetic mechanisms but 
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also on interaction with several microenvironmental cues. Within malignant brain 
tumours like GBM two distinct microenvironmental niches can be found which play an 
important role for induction, regulation and maintenance of brain tumour stem cells, 
the perivascular niche and the hypoxic niche. 
The tumour tissue in close proximity to blood vessels is called the perivascular niche. 
Due to the vasculature this niche is well supplied with oxygen and nutrients. It was 
shown that the perivascular niche contains cells associated to blood vessels with 
stem cell like phenotypes and stem cell marker expression (Calabrese et al., 2007). 
GBMs are fast growing highly proliferating tumours and have strong metabolic needs 
which cannot sufficiently served by the existing vasculature. It was shown that 
BTSCs of GBM can support neo-angiogenesis. Interestingly, blood vessels and brain 
tumour stem cells rely on a bidirectional regulation. BTSCs secrete VEGF (vascular 
endothelial growth factor) which induces angiogenesis (Bao et al., 2006b) and 
endothelial cells secrete themselves mitogens which activate the Notch pathway to 
maintain the brain tumour stem cell pool (Charles et al., 2010). The perivascular 
niche could be also a therapeutic target to indirectly eliminate BTSCs. Especially anti-
angiogenic treatments could help to starve out the stem cell population due to lack of 
nutrients and oxygen. An anti-VEGF treatment which is already in clinical use, 
Avastin (Bevacizumab), showed only limited clinical success because tumours of 
patients treated with this drug showed a more invasive behaviour than before (Paez-
Ribes et al., 2009) (Chinot et al., 2014; Gilbert et al., 2014; Haines and Gabor Miklos, 
2014).  
Regions of low oxygen tension due to severe necrosis or inefficient vasculature are 
not only histological hallmarks of GBMs but also a second niche for BTSCs (Pries et 
al., 2010). The molecular response to low oxygen availability is mainly regulated by 
HIFs (Hypoxia-inducible factors, HIF1α and HIF2α) (Bar, 2011; Li et al., 2009; Soeda 
et al., 2009). These factors are very important to maintain BTSCs and are closely 
linked to induction of angiogenesis. In particular, HIF2α promotes the expression of 
stem cell maintenance markers like Oct4 and Nanog, CD133, MAML3, ASPHD2 
(Covello et al., 2006; Heddleston et al., 2009; Seidel et al., 2010). Several 
experiments could show that the stabilisation of the HIF2α protein under hypoxic 
conditions or through expression of a non-degradable HIF mutant increased self-
renewal of BTSCs and enhanced the tumour formation in vivo, even in tumour cells 
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which showed no stem cell characteristics before (Heddleston et al., 2009) (Li et al., 
2009; Pietras et al., 2009; Seidel et al., 2010). HIF1α is known to induce the 
expression of the stem cell marker CD133 and increase the self-renewal of BTSCs 
(Soeda et al., 2009). 
In addition to the microenvironmental niches the TGFβ signalling pathway plays an 
important role in the regulation of CSCs. Despite the fact that TGFβ signalling is 
commonly found in tumours, so far there is only little known how TGFβ can influence 
CSCs. Nevertheless, some recent reports showed that in glioma TGFβ signalling is 
important for the maintenance of stem-like cells through the induction of the direct 
TGFβ target Sox4 which leads to accelerated expression of the stem cell marker 
Sox2 (Ikushima et al., 2009). Furthermore, it was reported that the self-renewal 
capacity of BTSCs in glioma relies on the induction of the cytokine LIF (leukaemia 
inhibiting factor) via TGFβ signalling (Penuelas et al., 2009). Through inhibition of the 
TGFβ pathway it was shown that this resulted in a decrease of the 
CD44(high)/Id1(high) population which is thought to represent BTSCs in glioma as 
well (Anido et al., 2010).  
Many of the above described signalling pathways, especially TGFβ and hypoxia, are 
also important for the induction of EMT. Interestingly, a number of recent studies 
suggest EMT is linked not only to the induction of mesenchymal features, but also to 
the acquisition of a CSC phenotype (Fig. 3.8). The strongest evidence was found in 
epithelial cancers like breast cancer. The cellular processes observed in cells 
undergoing EMT during cancer metastasis are analogous to the processes of tissue 
reconstruction by adult stem cells (Kondo et al., 2003). As an experimental approach 
naturally occurring stem cells isolated from immortalized human mammary epithelial 
cells, normal mouse mammary tissues and human reduction mammoplasty tissues 
were shown to express EMT markers. Moreover, induction of EMT through 
overexpression of Snail or Twist generated stem cell-like cells from differentiated 
transformed mammary epithelial cells stem-like cells can be generated in vitro, 
suggesting an important role of EMT in CSCs induction (Mani et al., 2008). 
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Fig. 3.8 Schematic model of CSC maintenance by EMT. Cells with an epithelial phenotype 
undergo EMT and are transformed into cells with mesenchymal expression patterns which 
share cancer stem cell traits. These CSC are able to initiate tumour formation, enhance 
tumour growth, invasion and migration of tumour cells to form distant metastasis and also 
contribute to tumour recurrence. Based on (Ouyang et al., 2010). 
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3.6 Aim of the study 
 
The importance of EMT regulators in invasion as a critical step in malignancy is very 
well elucidated in epithelial cancers but the mechanisms of glial to mesenchymal 
transition in solid tumour of the CNS, like glioma, is so far only partly understood. In 
this work we wanted to assess the role of GMT in tumour growth, invasion and the 
induction and maintenance of CSCs. Furthermore, we wanted to find out what role 
microenvironmental cues, such as hypoxia and TGFβ signalling, play in the induction 
of GMT. 
We first determined a set of markers suitable for the analysis of GMT. Next we 
examined the role of hypoxia and TGFβ signalling in controlling the expression of the 
key EMT factors of the Snail family. To address the functional significance of the 
EMT factors in the control of GMT we performed Snail/Slug loss of function 
experiments. Using stably transduced polyclonal pools of silenced cells we assessed 
the GMT phenotype by marker expression and by examining the invasive capacity of 
the cells. The involvement of the GMT regulators in tumour growth and invasion was 
examined by in vivo xenograft transplantation experiments. In addition, we 
investigated the functional role of Snail and Slug in the regulation of the cancer stem 
cell phenotype.  
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 4. Results 
4.1. Expression of Snail and Slug in the different molecular subclasses of 
glioblastoma 
 
To examine the specific expression of EMT regulators Snail and Slug (SNAI1,SNAI2) 
in the molecular subclasses of glioblastoma  we carried out a bioinformatic analysis 
of glioblastoma expression datasets from “The Cancer Genome Atlas” (TCGA). The 
mRNA expression data of the EMT regulators was downloaded from the publicly 
available datasets for GBM with neural, proneural, mesenchymal and classical gene 
signature (TCGA, 2008; Verhaak, 2010). The analysis showed that Snail and Slug, in 
line with their known function in other cancers, are significantly upregulated in 
tumours with a mesenchymal gene signature and downregulated in proneural, neural 
and classical subtypes (Fig. 4.1).  
 
 
Fig.4.1 SNAI1 and SNAI2 are overexpressed in the mesenchymal glioblastoma 
subtype. mRNA expression of SNAI1 and SNAI2 in GBM with proneural, neural, 
mesenchymal and classical gene signature. The significances were calculated versus the 
mesenchymal subclass. **p < 0.01, ***p < 0.001  
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4.2 Regulation of Snail and Slug expression and induction of GMT by 
environmental signals  
 
Fig. 4.2 Hypoxic induction of Snail Western blot analysis of different glioma cell lines, 
showing induced Snail expression when exposed to 1% oxygen for 18 h, compared to 
normoxic (21% oxygen) controls. 
 
EMT/GMT is regulated by environmental cues, such as hypoxia and TGFβ. These 
triggers lead to an upregulation of transcriptional regulators like Snail and Slug as 
well as markers like vimentin and N-cadherin, accompanied by a downregulation of 
markers like E-cadherin, as a part of the induction of the EMT programme. 
To find out if the expression of Snail is induced by low oxygen concentrations several 
glioblastoma cell lines were cultured either under normoxic (21% O2) or hypoxic (1% 
O2) conditions for 18 hours (Fig. 4.2). We used GBM10, GBM18 and GBM37x 
primary cell lines isolated from patient tumour samples, as well as LN229x, an 
established human glioma cell line that was re-isolated from a mouse xenograft. The 
analysis of protein levels by Western blotting showed a hypoxic induction of Snail, in 
comparison to the normoxic control, in several glioblastoma cell lines (Fig. 4.2). 
However the common markers for EMT like vimentin and N-cadherin showed no 
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regulation, upon hypoxic treatment in the glioblastoma cells used (data not shown). 
Furthermore E-cadherin showed no expression in our GBM lines. These results show 
that though hypoxia induces EMT regulator Snail this is not sufficient for the induction 
of typical EMT markers in glioblastoma. 
 
 
Fig. 4.3 Regulation of Snail and Slug expression and induction of GMT by 
environmental signals. TGFβ treatment (2.5 ng/ml for 3,5 or 7 days) induced Snail and 
Slug expression and regulated a set of markers corresponding to the transition from a 
proneural to a mesenchymal phenotype.  
 
We next sought to determine the effect of TGFβ, the classical inducer of EMT on 
glioblastoma cells. G55 cells, an established glioma line, were treated with 2.5 ng/ml 
TGFβ for either 3, 5 or 7 days. As shown in Fig. 4.3 the expression levels of Slug and 
especially of Snail were strongly upregulated upon TGFβ treatment at all time points. 
Similarly to our findings following hypoxic exposure, however, the classical EMT 
markers vimentin and N-cadherin showed no consistent regulation upon TGFβ 
treatment. Therefore we aimed to determine whether alternative markers could be 
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found, which could be linked to the transition from a proneural to a mesenchymal 
phenotype. Based on literature research and expression profiling data (Phillips et al., 
2006; Verhaak et al., 2010) we decided to test several possible markers to 
distinguish if cells are undergoing GMT and if this is accompanied to the acquisition 
of a cancer stem cell phenotype. 
We used YKL40 as a mesenchymal marker, Olig2 as a proneural marker and 
ASPHD2 as a marker for stemness (Phillips et al 2006, Seidel et al 2010). Indeed, 
following TGFβ treatment G55 cells showed an upregulation of the mesenchymal 
marker YKL40 and the stemness marker ASPHD2 (Fig. 4.3). Consistently, Olig2 as 
proneural marker showed a stable downregulation when cells were treated with 
TGFβ (Fig. 4.3). 
 
4.3. The loss of Snail and Slug impairs GMT and the establishment of a cancer 
stem cell phenotype 
 
 
Fig. 4.4 The loss of Snail and Slug does not impair the expression of the classical EMT 
markers N-cadherin and vimentin. Western blot analysis of Snail and Slug deficient cells 
demonstrating no changes in the expression of N-cadherin and vimentin. GBM046x and G55 
cells were treated with 2.5 ng/ml TGFβ1 for 3 days. 
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Snail and Slug were highly upregulated by TGFβ during the induction of EMT/GMT, 
suggesting that they play an important role in this process. To directly test this, we 
examined the phenotype of Snail, Slug or Snail/Slug deficient cells. GBM046x and 
G55 cells were stably transduced with lentiviruses carrying a vector containing a 
shRNA to silence either Snail or Slug or both together (Fig. 4.4). First, we checked 
the expression of the classical marker N-cadherin and vimentin in these knock-down 
pools. Consistent with our earlier findings, we could not observe any changes in 
protein levels of N-cadherin and vimentin following TGFβ treatment or silencing of 
either Snail, Slug or both (Fig. 4.4).  
 
 
Fig. 4.5 Expression of GMT markers in glioma molecular subgroups. Analysis of the 
TCGA database showed that the panel of markers used in this work are differentially 
expressed in the different molecular subclasses of GBM. Significances were calculated 
versus the mesenchymal subclass. *p < 0.05, ** p < 0.01, ***p < 0.001  
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We next went on to establish a panel of markers that could be suitable for the 
distinction between proneural and mesenchymal states in glioblastoma. We focused 
on markers that have been previously proposed in expression profiling studies 
including MAP2, Olig2, and T-cadherin as proneural/glial marker, as well as CD44, 
CDH11 and YKL40 as mesenchymal markers (Phillips 2006, Verhaak 2010, Carro 
2010). As a first step we analysed the expression of these markers in the TCGA 
glioblastoma dataset (Fig. 4.5). We found that MAP2, T-cadherin and Olig2 were 
significantly reduced in the mesenchymal subgroup compared to the proneural group. 
CD44, CDH11 and YKL40 showed a significant increase of expression in tumours 
classified for the mesenchymal subgroup compared to the proneural subgroup (Fig. 
4.5)  
Immunoblotting (Fig. 4.6) and an analysis of mRNA levels (Fig. 3.7) of the markers in 
GBM046x and G55 cells showed that they are prominently regulated through the 
addition of TGFβ1. The proneural markers MAP2, Olig2 and T-cadherin exhibit a 
reduced expression when control cells were treated with TGFβ1, whereas the 
mesenchymal markers CD44, YKL40 and CDH11 as well as the stemness marker 
ASPHD2 showed an upregulation when GMT was induced by TGFβ1 in control cells. 
Importantly, silencing of Snail and Slug largely reversed the TGFβ1 induced GMT 
transition (Fig. 4.6). Quantitative real-time PCR showed that the loss of Snail and 
Slug induced strongly the expression of the proneural marker T-cadherin and 
reduces the expression of the mesenchymal markers CDH11 and CD44 in GBM046x 
and G55 cells (Fig. 4.7). 
The markers MAP2, Olig2, CD44, ASPHD2 were not altered or changed in a 
direction corresponding to a transition from a mesenchymal to a proneural state upon 
single silencing of Snail or Slug, but Snail/slug double knockdown induced a 
pronounced shift to a proneural phenotype. On the other hand for the mesenchymal 
marker YKL40 single Snail and Slug knockdowns induced a partial mesenchymal to 
proneural transition, but the effects of the combined Snail/Slug knockdown were 
again typically more potent. Thus, while silencing of either Snail or Slug was sufficient 
to alter the expression of some of the proneural and mesenchymal markers, 
combined silencing of Snail and Slug had the most profound and robust effects, 
inducing a shift from a mesenchymal to a proneural state under TGFβ1 stimulation. 
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Taken together, these results demonstrate that the transcription factors Snail and 
Slug play a synergistic, partially redundant role in the regulation of GMT and the 
acquisition of cancer stem cell traits. 
 
Fig. 4.6 The loss of Snail and Slug inhibits a complete glial to mesenchymal transition. 
A+B Immunoblotting of GMT markers in GBM046x and G55 after TGFβ1 stimulation, 
showing that cells with silenced Snail and Slug expression are not able to complete the 
transition from a proneural to a mesenchymal phenotype. (For knock-down efficiency see 
Fig. 4.4)  
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Fig. 4.7 The loss of Snail and Slug impairs the mRNA expression of GMT markers. 
Analysis of mRNA levels of GMT markers, showing that the loss of Snail and Slug impairs 
the transition from proneural to mesenchymal phenotype. 
 
4.4 Snail and Slug influence the cancer stem cell phenotype of GBM cells 
 
The regulation of glioma stem cell markers such as ASPHD2 by Snail/Slug silencing 
(see Fig. 4.6A, B), suggested that Snail and Slug are involved in the control of cancer 
stem cell expansion or maintenance. To further investigate if cell stemness is 
connected to the expression of GMT regulators we performed fluorescence activated 
cell sorting (FACS) to assess the expression of the surface marker CD15 which is 
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commonly used as a stem cell marker (Read et al., 2009) (Fig. 4.8A). Interestingly, 
GBM046x cells lacking Snail and Slug showed a significantly smaller population of 
cells with high CD15 expression in FACS compared to the control cells (Fig. 4.8A). 
Furthermore Snail/Slug knockdown cells also exhibit a reduced expression of cancer 
stem cell markers, such as MAML3, SOX2 and OCT4 (Fig. 4.8B). 
 
Fig. 4.8 Snail and Slug influence the expression of CSC markers. A FACS analysis of 
CD15 showed reduced expression in Snail and Slug deficient cells. B The expression of the 
stem cell markers MAML3, OCT4 and SOX2 is reduced in shSnail/Slug cells. **p < 0.01 
 
To functionally confirm that Snail and Slug are involved in stem cell regulation we 
performed a sphere formation assay for GBM046x and G55 cells (Fig. 4.9). This 
assay examines the ability of single GBM cells to self-renew and form gliomaspheres 
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in suspension culture conditions, which is one of the key read-outs for the self-
renewal potential of normal and cancer stem cells. Seven days after seeding the 
single cells, the formed gliomaspheres were counted and the percentage of sphere 
forming units (SFU) was assessed. These experiments demonstrated that combined 
silencing of Snail and Slug suppressed the glioma cell self-renewal significantly, with 
Snail playing an apparently dominant role in GBM046x in this context (Fig. 4.9).  
 
 
Fig. 4.9 Snail and Slug control the self-renewal ability of glioma cells. Sphere formation 
assays showing that the self-renewal capacity of Snail/Slug deficient cells is significantly 
reduced. Scale bars represent 200 µm. **p < 0.01, ***p < 0.001  
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Taken together, these results show that concomitantly with their effects on GMT, 
Snail and Slug are important regulators of the glioma stem cell phenotype. As 
combined silencing of Snail and Slug had more robust and consistent effects on the 
capacity of glioblastoma cells to undergo GMT and on their stem cell phenotype 
compared to individual knockdown of Snail or Slug, we focused our further 
experiments on cells with simultaneous Snail and Slug loss.  
 
4.5 Apoptosis and proliferation of GBM cells in vitro is not impaired by the loss 
of Snail and Slug 
 
Snail and Slug are also thought to be involved in proliferation and/or apoptosis in 
vitro as well as in patients (see section 3.3.3). To determine the role of Snail and Slug 
in cell death and proliferation we performed immunofluorescence stainings of 
apoptotic cells with the TUNEL assay. Proliferative cells were analysed by staining 
for BrdU (Bromodeoxyuridine), incorporated in the DNA during S-phase (Fig. 4.10A, 
B). Quantification of the stainings showed that the loss of Snail and Slug had no 
significant effect on the amount of apoptotic or proliferative cells in GBM046x and 
G55 cells (Fig. 4.10A, B). 
 
 
Fig. 4.10 The loss of Snail and Slug does not affect apoptosis and proliferation in vitro. 
A Quantification of TUNEL staining of GBM046x and G55 cells showed no significant 
differences in the amount of apoptotic cells between control and shSnail/Slug cells. B 
Quantification of BrdU staining of GBM046x and G55 cells showed no significant differences 
in the amount of proliferating cells between control and shSnail/Slug cells. 
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4.6. The loss of Snail and Slug impairs the invasiveness of GBM cells in vitro 
 
 
Fig. 4.11 The loss of Snail and Slug impairs the invasiveness of glioblastoma cells 
through matrigel. Modified Boyden chamber assay showed that GBM046x and G55 cells 
have a severely reduced ability to invade through a matrigel covered filter when Snail or 
Snail /Slug are silenced. Scale bars represent 100 µm *p < 0.05, ***p < 0.001  
 
A central characteristic of the mesenchymal phenotype is enhanced cell 
invasiveness. In the context of GBM this could be reflected by an accelerated 
infiltration of tumour cells away from the tumour mass into the surrounding brain 
parenchyma. To assess the role of Snail and Slug in GBM cell invasion we performed 
in vitro Invasion assays (Fig. 4.11, 4.12). First we used a modified Boyden chamber 
assay to assess the ability of the cells to invade through a polystyrene filter with a 
pore size of 8 µm coated with a layer of matrigel, which serves as a model of the 
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basal lamina. The invasion rate of the cells was examined after 18 hours of invasion. 
Importantly in both GBM046x and G55 cells silencing of Snail and Slug significantly 
reduced invasion. Interestingly, in GBM046x cells the single knock-down of Snail 
seemed to be sufficient to reduce the invasive capacity of the cells in this assay. The 
observed effect of strongly reduced invasion in the Snail and Slug deficient cells 
seemed to be presumably due to the silencing of Snail since the knock-down of Slug 
increased the invasion of the cells (Fig. 4.11). By contrast, in G55 cells the modified 
Boyden chamber assay showed clearly that only combined Snail and Slug deficiency 
significantly impaired in invasion through the matrigel layer (Fig. 4.11). Single 
silencing of Snail or Slug alone had no effect on the invasiveness of the cells. 
To provide further support for the role of Snail and Slug in glioblastoma cell invasion 
we performed an additional assay, namely a collagen invasion assay. This assay 
resembles the natural conditions of cancer cell invasion through an extracellular 
matrix. The cancer cells are embedded as a small gliomasphere into a layer of 
collagen, which is a part of the extracellular matrix, allowing the cells to invade in a 
three dimensional manner. By capturing microscope images every 24 hours we were 
able to follow the process of invasion. The ability of the cells to invade into the 
collagen was quantified using the invasion index formula,                                    
invasiveness= (Perimeter)2 / Area (Siebzehnrubl et al., 2013).  
The obtained results supported the data of the modified Boyden chamber assay, by 
demonstrating that silencing of Snail and Slug markedly reduced invasion. In 
GBM046x cells silencing of Snail was sufficient to impair the invasiveness in collagen 
after 24 and 48 hours (Fig. 4.12), in accordance with the results from the Boyden 
chamber assay. In G55 cells, on the other hand the silencing of either Snail or Slug 
alone had no significant effects on the three dimensional invasion in the collagen 
matrix. However, combined loss of Snail and Slug strongly impaired the capacity of 
G55 cells to invade collagen (Fig. 4.12). 
Taken together, these finding suggest a prominent role for Snail and Slug in the 
regulation of invasion in GBM which seems to be closely connected to the regulation 
of GMT. 
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Fig. 4.12 Snail and Slug deficiency reduces the ability of glioblastoma cells to invade 
into collagen Collagen invasion assay of a tumoursphere showed that the invasion capacity 
of shSnail and shSnail/Slug cells is highly impaired. Scale bars 100 µm. *p < 0.05, ***p < 
0.001 
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4.7. Snail and Slug deficient cells show reduced tumour growth 
  
 
Fig. 4.13 Snail and Slug deficiency reduces intracranial glioma growth.                          
A Representative hematoxylin/eosin staining of GBM046x and G55 control and shSnail/Slug 
tumours (40 µm thick section). Snail and Slug deficient cells showed a significantly reduced 
tumour volume. Scale bars represent 1mm. **p < 0.01  
 
Given the effects of silencing Snail and Slug on GMT and stemness, we next wanted 
to assess if Snail and Slug are involved in the control of tumour growth in vivo. The 
Snail/Slug deficient cells were pretreated with TGFβ1 and then intracranially injected 
into immuno-deficient nude mice. After the mice started to show neurological 
symptoms typically associated with brain tumour growth and the development of 
increased intracranial pressure, they were sacrificed and perfused with 4% PFA to fix 
the tumour tissue. The tumour growth in the brain was assessed by measuring the 
tumour volume in hematoxylin and eosin (H&E) staining of serial sections (Fig. 4.13). 
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The tumours of GBM46x and G55 cells with silenced Snail and Slug showed a 
significantly smaller size compared to the control group (Fig. 4.13), consistent with 
our findings of an important functional role of Snail and Slug in GMT and glioma stem 
cell maintenance.  
 
4.8. The loss of Snail and Slug does not impair apoptosis, proliferation or 
vascularisation in vivo 
 
To further asses the reasons for the reduced growth of Snail and Slug silenced 
tumours we also examined the effects on apoptosis and proliferation of tumour cells 
in vivo as well as the vascularisation of the tumour itself. 
To visualize apoptotic cells, 40 µm thick sections of the GBM046x and G55 tumours 
we used a TUNEL assay (Fig. 4.14). Quantification of the stained cells showed that in 
both tumours no difference in the number of apoptotic cells per mm2 was observed 
between control group and the Snail/Slug double knockdown group (Fig. 4.14). Thus, 
we could rule out that a higher apoptosis rate in the double knockdown group is the 
reason for the smaller tumour volume.  
Differences in tumour growth can be often explained through effects on cell 
proliferation. Proliferating cells are detectable when stained for the phosphorylated 
form of histone 3 on the highly conserved Ser-10 residue. This phosphorylation event 
is a read out for the onset of mitosis. Staining of tumours from GBM046x and G55 
cells for phospho-histone 3 showed no significant difference between control and 
Snail/Slug silenced tumours (Fig. 4.15), indicating that reduced tumour growth of 
Snail/Slug double knockdown cells cannot be explained by impaired proliferation. 
Another reason for slower growth could be a reduced vascularisation of the tumour. 
Neovascularisation and co-opted brain vessels are needed by the tumour for 
suffiencient oxygen and nutritional supply. To asses tumour vascularisation we 
performed an immunofluorescence staining for endomucin, a protein present on the 
surface of blood vessel endothelial cells (Fig. 4.16). Quantification of the ratio of area 
covered by vessels to total analysed tumour area showed that the vascularisation of 
the tumour was also not affected through the silencing of Snail and Slug (Fig. 4.16). 
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Fig. 4.14 The loss of Snail and Slug does not impair apoptosis of tumour cells. 40 µm 
tumour sections were stained for apoptotic cells using a TUNELassay. Positively stained 
cells/mm2 were quantified. Scale bar represents 100 µm. 
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Fig. 4.15 The loss of Snail and Slug does not impair proliferation of tumour cells. 40µm 
thick tumour sections were stained for proliferating cells using an antibody against phospho-
histone 3. Positively stained cells/mm2 were quantified. Scale bar represents 100 µm.   
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Fig. 4.16 The loss of Snail and Slug does not impair vascularisation of the tumour. 40 
µm tumour sections were stained for blood vessels using an antibody against the endothelial 
protein Endomucin. The stained vessel area was quantified. Scale bar represents 100 µm.   
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4.9. The loss of Snail and Slug impairs the invasiveness of GBM cells in vivo 
 
 Fig. 4.17 The invasiveness of cancer cells in vivo is significantly reduced by silencing 
Snail and Slug. GFP expressing control cells or shSnail/Slug GBM046x or G55 cells were 
orthotopically transplanted into nude mice to monitor the invasive behaviour of the cells. 
Cells with silenced Snail/Slug expression showed a drastic reduction of invasion into the 
surrounding brain parenchyma.  Pictures of GBM046x tumours were taken with 10x 
magnification; Pictures of G55 tumours were taken with 20x magnification. Scale bars 
represent 100 µm. **p < 0.01, *** p < 0.001  
 
In our in vivo experiments we were able to use the GFP signal of the transduced cells 
to assess the invasive area. 40 µm thick sections of the brain were mounted and 
pictures were taken with a fluorescence microscope (Fig. 4.17). Both the GBM046x 
and G55 tumours showed a striking effect on invasion when Snail and Slug were 
silenced, as apparent through the strong reduction of invading cells leaving the 
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tumour mass in the double knock-down cells compared to the control cells . Analysis 
of the invasive area of the tumours showed that the invasion of tumour cells was 
significantly reduced in the Snail and Slug double knockdown group in comparison to 
the control tumours (Fig. 4.17). 
These findings support our hypothesis that invasion, the key feature of EMT in 
epithelial cancers is also controlled by the transcriptional regulators Snail and Slug in 
non-epithelial gliomas. 
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5. Discussion 
 
In this work we demonstrate that the EMT/GMT regulators Snail and Slug play a 
crucial role for the transition from a glial to mesenchymal phenotype in glioblastoma. 
Furthermore, Snail and Slug are involved in the induction or maintenance of cancer 
stem cells by regulating the self-renewal capacity of the cells, indicating a coupling 
between mesenchymal and stem cell traits in GBM. Consistently, tumour growth and 
the invasiveness of glioma cells depend on these EMT/GMT factors. These findings 
identify common key mechanisms controlling the transition between epithelial/glial 
and mesenchymal states in epithelial and glial tumours, and highlight the importance 
of Snail family EMT regulators as potential targets for glioblastoma therapy. 
 
5.1 The molecular subclassification of GBM 
 
The first indications that glioblastoma cells can possess mesenchymal characteristics 
were based on genome-wide molecular profiling studies that allowed a classification 
of GBM into distinct subtypes. 
The first publication that proposed a classification of GBM in three different molecular 
subclasses used a microarray based expression analysis of high-grade astrocytoma 
sample sets (Phillips et al., 2006). It defined three distinct subgroups of tumours by 
identifying a robust set of signature genes, chromosomal aberrations and possible 
cells of origin: proneural, mesenchymal and proliferative. 
The proneural (PN) subgroup included a mixture of WHO-grade III and IV gliomas 
with or without necrosis. The specific signature gene set for PN tumours included 
genes such as the Notch ligand delta.like ligand 3 (DLL3) and brevican (BCAN). 
Furthermore, markers like Olig2 (oligodendroglial marker 2), MAP2 (microtubule 
associated protein 2) and the neuronal marker NeuN, which are related to 
neuroblasts or developing neurons showed an overexpression in this group.  
The mesenchymal (Mes) and proliferative (Prolif) subgroup consisted nearly 
exclusively of WHO grade IV tumours with necrosis. The microarray analysis showed 
that the Mes group of tumours is characterised by the overexpression of markers like 
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the chitinase-like protein YKL40, the cell surface glycoprotein CD44 or the 
transcription factor STAT3 (signal transducer and activator of transcription 3). In this 
subgroup genes important for angiogenesis, such as VEGF (vascular endothelial 
growthfactor) and its receptors, as well as the endothelial marker PCAM1, are also 
upregulated. Interestingly, the mesenchymal subgroup showed also a correlation to 
the expression of stemness markers like Nestin or CD133. The Prolif group of 
tumours was classified by the expression of proliferation related markers like 
proliferating cell nuclear antigen (PCNA) or TOP2A (topoisomerase 2A).  
In 2010 a study of gene expression in the glioblastoma cohort of The Cancer 
Genome Atlas (TCGA) refined the classification of the GBM subtypes (Verhaak et al., 
2010). According to this classification GBM is subdivided into 4 molecular groups: 
classical, mesenchymal, proneural and neural.  
In their study the authors classified the classical subtype by genetic aberrations of 
chromosome 10 and 7, amplification of the EGFR (epidermal growth factor receptor) 
gene, lack of TP53 mutations and aberrations of components of the RB 
(retinoblastoma tumour suppressor) pathway (important for DNA replication and 
transcription). Expression data showed an overexpression of neural precursor and 
stem cell marker nestin and high expression of components of the notch and sonic 
hedgehog pathways. 
The mesenchymal class was characterised by the deletion of the tumour suppressor 
NF1 (neurofibromin 1) gene and the strong expression of YKL40 and CD44. Thus the 
definition of the mesenchymal subtype overlaps with that of (Phillips et al., 2006) 
which was based on a combination of grade II and grade IV gliomas. Additionally, 
they show an upregulation of members of the NFκB pathway probably due to higher 
overall necrosis and associated inflammatory infiltrates in this tumour subtype. 
In the proneural subtype they were able to show a high frequency of alteration 
leading to an overexpression of PDGF (platelet derived growth factor) receptor A 
(found in all subtypes but the highest percentage is in the proneural class), as well as 
IDH1 (isocitrate dehydrogenase 1) point mutations. Again in accordance with the 
previously discussed study (Phillips et al., 2006) they found an elevated expression 
of oligodendrocytic development genes like DLL3 and Olig2 and others (Verhaak et 
al., 2010).  
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The neural subtype is characterised by the high expression of neuronal markers like 
NEFL (neurofilament light polypeptide), GABRA (gamma-aminobutyric acid (GABA) 
receptor A), the calcium sensor SYT1 and the potassium/chloride transporter 
SLC12A5. Interestingly, the different subtypes of GBM show distinct variations in 
survival benefit of the patients upon different therapies. A common treatment of GBM 
is the combination of the alkylating agent temozolomide with radiation. Heavily 
treated patients with tumours of the proneural group showed no beneficial effects on 
survival, whereas patients with tumours belonging to the classical or mesenchymal 
subgroup showed delayed mortality. 
A further study examined the variation of DNA methylation patterns among different 
GBM samples of the TCGA collection, revealing additional important features of the 
distinct tumour subtypes (Noushmehr et al., 2010). The authors showed that a large 
number of loci are hypermethylated only within the proneural subtype. This indicates 
the presence of a glioma CpG island methylator phenotype (G-CIMP) as previously 
described for colorectal cancer (Toyota et al., 1999). Interestingly, G-CIMP tumours 
showed altered expression of a panel of genes associated with patient outcome, 
markers of the mesenchyme, tumour invasion and extracellular matrix. In conclusion, 
the lack of this silencing methylation phenotype could lead to the development of 
more aggressive tumours, especially in the mesenchymal subtype, which lacks CpG 
island hypermethylation. 
Subsequent work combining methylation, expression and mutational analyses of 
GBM samples uncovered further subgroups of GBM tumours, highlighting the 
heterogeneity of these tumours (Sturm et al., 2012). Sturm and co-workers performed 
a genome-wide methylation pattern analysis but combining adult and pediatric GBM 
samples. They were able to define six distinct methylation clusters. Based on 
correlation with mutational status, DNA copy number aberrations and gene 
expression signatures they classified six biological subgroups as followed: 1. IDH 
mutated (mostly correlating with the proneural subgroup), 2. Histone 3.3 (H3F3A) 
K27 mutated (mostly pediatric samples and correlated to proneural subtype), 3. 
Histone 3.3 (H3F3A) G34 mutated (pediatric GBM), 4. RTK I (typically involving 
PDGFRA amplification), 5. Mesenchymal, 6. RTK II (correlated with the classical 
subtype). Interestingly, their definition of the mesenchymal subgroup is not fully 
comparable to the other studies since they combined in this group all cases that did 
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not completely fit in one of the other five. The mesenchymal class here consists of 
samples that showed the highest similarity to normal brain methylation pattern, have 
a much lower incidence of GBM related copy number aberrations, fewer copy 
number changes and no characteristic point mutations. Nevertheless, this study 
could give a deeper insight into how epigenetic mechanisms especially mutation of 
K27 in Histone 3 could be important to further subclassify GBM tumours. 
The first experimental study taking advantage of the classification of GBM subtypes 
showed that patient derived glioma spheres that resemble either PN or Mes 
phenotypes (tested by expression of markers and existence of G-CIMP cluster) differ 
in their biological characteristics (Bhat et al., 2013). After the isolation of the cells 
most of the samples derived from Mes tumours lost the typical Mes phenotype and 
shifted toward a PN phenotype following in vitro culturing or transplantation as 
xenografts. The cells showed a loss of YKL40 and a gain of Olig2 expression, as well 
as gain of G-CIMP. All this suggesting a lack of microenvironmental signals which are 
necessary for the maintenance of a mesenchymal phenotype in cell culture 
conditions and in mouse xenografts. As reported in the previous studies the 
mesenchymal subclass shows an upregulated activity of the NF-κB pathway, 
therefore the authors treated the isolated cells with cytokines known to activate the 
NF-κB pathway. They tested IL6, IL8, IL10, TGFβ and TNFα, showing that only TNFα 
had a striking effect on the expression of CD44, CD15 and YKL40. Transcriptomic 
analysis showed that the treatment with TNFα induced a shift from a proneural back 
to a mesenchymal signature. This analysis also revealed that transcription factors 
known to induce a mesenchymal signature such as STAT3, C/EBPβ and TAZ were 
significantly upregulated. Interestingly, transcription factors directly related to EMT, 
namely Snail1, Slug and TWIST1 showed no differential expression. Furthermore, 
overexpression of the Mes signature genes CD44 and CD15, as well as the NF-κB 
activation correlated with poor radiation response and shorter survival in patients. 
Taken together these studies demonstrate the utility of GBM subclassification, which 
can have both prognostic value and therapeutic importance. The studies suggest that 
different subtypes of GBM may benefit from different types of therapy; therefore 
assays for the diagnosis of GBM subtype could represent a useful addition to current 
molecular diagnostic markers for GBM.  
 
Discussion 
51 
 
5.2 The distinctive features of EMT and GMT 
 
So far there are few reports showing EMT in CNS cancers such as glioma and the 
terminology related to the study of this process in brain tumours remains a point of 
debate. Indeed, since the brain is lacking typical epithelium and mesenchyme the 
use of an alternative terminology is warranted. Therefore we propose the term glial-
to-mesenchymal transition (GMT), or proneural-to-mesenchymal transition with 
regard to the marker expression in the different molecular subclasses of glioma.  
Epithelial cell layers outside the CNS are characterized by close cell-cell contacts 
including tight junctions, adherens junctions and desmosomes. A major component 
mediating epithelial cell-cell attachment in these structures is E-cadherin. The 
epithelial cells show an apical and basolateral polarisation and a tight connection to 
the basal membrane. During EMT in normal development or carcinogenesis the cells 
change from well differentiated polarized epithelial cells to unpolarised migratory 
mesenchymal cells with changes in expression of marker genes like vimentin and N-
cadherin. To manage these morphological changes a rearrangement of the 
cytoskeleton and the ECM has to occur as well.  
Although glial cells in the brain have a neuroepithelial origin, they are not as strictly 
organised as epithelial cell layers. They also have cell-cell contacts mediated mainly 
by cadherins such as N-cadherin and CDH11 as well as NCAM (Sakisaka and Takai, 
2005).  
In our work we faced the problem that the classical markers often used to determine 
EMT, such as E-cadherin, N-cadherin or vimentin were either not expressed in 
glioma cells or did not show any response to EMT induction by major triggers like 
hypoxia (data not shown) or TGFβ treatment (see Fig. 4.4). Therefore we examined 
the reports of the molecular subclassification of GBM to find a panel of reliable 
markers to monitor GMT in our glioma cell lines. After testing many of the proposed 
signature genes we were able to validate a working set of GMT markers. To 
determine the mesenchymal state of the cells we used CD44 (also used as marker 
for stemness), YKL40 and CDH11. The utility of some of these markers was already 
reported before. YKL40 was shown to play a role in promotion of glioma growth, 
malignancy, radio-resistance and angiogenesis and is overexpressed in glioma 
patient with poor prognosis (Francescone et al., 2011). The literature on the calcium 
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dependent cell adhesion molecule CDH11 is somewhat more controversial. In 2012 
and 2013 it was shown that CDH11 can act as a mesenchymal marker, due to its 
expression in stem-like glioma cells and glioma tissue samples. Furthermore, 
silencing of CDH11 led to decreased invasion and cell survival in vitro and in vivo 
(Kaur et al., 2012; Schulte et al., 2013). Nearly at the same time a study was 
published showing that CDH11 is downregulated at the invasive front in GBM patient 
samples and that the silencing of CDH11 leads to increased invasion (Delic et al., 
2012). In our experiments YKL40 and CDH11 proved as reliable markers for the 
mesenchymal phenotype, whose expression was reduced upon the loss of Snail and 
Slug (see Fig.4.7).  
As proneural markers we utilised MAP2, T-cadherin and Olig2. For MAP2 it was 
shown recently that in glioma cells the PKA (protein kinase A) pathway gets activated 
by upregulated MAP2 expression, which leads subsequently to a reduction of the 
invasive capacity of the cells (Zhou et al., 2015). T-cadherin was previously used to 
show in highly invasive VEGF knock-out mouse astrocytoma cells, stimulated with 
HGF, a transition comparable to EMT. These cells showed an increase in Snail 
expression and a subsequent decrease of T-cadherin expression upon HGF 
treatment (Lu et al., 2012). The role of Olig2 in glioma is more ambiguous. Some 
groups use it as a stem cell marker (Hjelmeland et al., 2011; Trepant et al., 2015) but 
the molecular classification approaches identified it clearly as a marker for the 
proneural subclass. In our study Olig2 behaved as a proneural marker that was 
consistently downregulated by signals that induce EMT/GMT, such as TGFβ (see 
Fig.4.3). Also the silencing of Snail and Slug restored the reduced Olig2 expression 
after TGFβ stimulation to an even higher extend than in the untreated control cells 
(see Fig. 4.5). These results and the molecular subclassification of GBM are clearly 
arguing for Olig2 as a proneural marker. 
Taken together, our results identify and validate a reliable panel of markers to 
monitor the transition between a proneural state and a mesenchymal state of the 
cells during TGFβ-mediated GMT.  
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5.3 The importance of Snail and Slug in GMT in glioblastoma multiforme 
 
As shown in our data Snail and Slug play a crucial role in regulating GMT and 
stemness in glioma. They do not influence the classical markers N-cadherin and 
vimentin known from epithelial cancers. However, cells with silenced Snail and Slug 
show impaired transition from a glial/proneural to a mesenchymal state, as evidenced 
by changes in the expression of several markers on protein and mRNA level. 
Interestingly, the relative contribution of Snail and Slug to the regulation of individual 
markers, such as YKL40 or CDH11, and cellular functions such as self-renewal and 
invasion appear to be different and in part cell line dependent (see. Fig 4.6; 4.7; 4.9). 
For example in the primary cell line GBM046x the self-renewal capacity and the 
invasiveness of the cells is primarily affected by silencing Snail (see Fig. 4.11; 4.12). 
On the whole, however, GMT, stemness and invasion are more consistently and 
more robustly suppressed by combined silencing of Snail and Slug than by the loss 
of either factor individually. 
Interestingly, a couple of recent reports show a potential strong involvement of Snail 
and Slug in invasiveness and stemness of glioma cells but concentrated only on 
silencing or overexpressing one of the SNAI family members.                                                  
A genome-wide expression profiling of human glioma samples showed that tumours 
with increased in vitro proliferation and invasion had an upregulation of Slug. Slug 
overexpressing cells exhibited in vivo promoted angiogenesis and elevated tumour 
growth. Enhanced invasiveness could be abrogated by silencing Slug and 
subsequent animal studies showed an increased survival of mice bearing Slug 
silenced tumours (Yang et al., 2010). Two recent reports showed comparable results 
for Snail. By silencing Snail expression it was observed that the cells showed a 
reduced expression of vimentin and a subsequent upregulation of E-cadherin 
together with decreased proliferation, retarded cell cycle and impaired 
invasion/migration of the cells in vitro(Han et al., 2011; Myung et al., 2014). 
Furthermore, it was found that Snail supresses the microRNA miR128, a known 
tumour suppressor involved in regulating the expression of SP1, by binding to the 
miR128 promoter region. SP1, in turn, regulates the cell cycle, tumour formation and 
growth, as well as migration of tumour cells (Dong et al., 2014).                                                                                 
Another study reported that irradiation leads to elevated levels of Snail in glioma 
cells, which promotes GMT. Murine tumour specimens taken after irradiation cycles 
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showed higher migratory and invasive capacity, as well as upregulated Snail 
expression. Again these effects were reverted by silencing of Snail. Interestingly the 
irradiated cells showed in addition an elevated expression of the stemness marker 
SOX2 and a tumour initiating potential (Mahabir et al., 2014).  
With our study we are able to confirm for the first time that Snail and Slug together 
are important to induce a complete transition from a glial/proneural to a more 
mesenchymal phenotype with concomitant increase in cell invasiveness and stem 
cell capacity. Furthermore, we also examined in detail the effects of the loss of Snail 
and Slug on tumour growth in orthotopic intracranial xenografts. We showed that 
combined silencing of Snail/Slug reduced tumour volume and invasion but did not 
affect proliferation, apoptosis or vascularisation. 
A study in 2013 found that stimulation of glioblastoma cells with BMP7 (bone 
morphogenetic protein 7), a member of the TGFβ superfamily, induces Snail in a 
SMAD1/5-dependent manner. They could show that glioma cells overexpressing 
Snail exhibit elevated invasive behaviour in a xenograft model. Surprisingly, however, 
overexpression of Snail led to decreased tumour sphere formation in vitro and 
reduced tumorigenicity, an effect that the authors attributed to the known capacity of 
BMPs induce differentiation of stem-like cells (Savary et al., 2013). It is conceivable 
that BMP7-driven Snail expression activates different signalling mechanisms, which 
leads to a dissociation of the invasive capacity of GBM from the stemness and the 
tumorigenic potential of the cells. At the same time, it has to be noted that these 
findings were based on Snail overexpression experiments, which may cause 
secondary effects in the cells, due to impaired homeostasis of protein synthesis and 
folding and the activation of pathways that are not induced by normal amounts or 
through natural triggers of the respective protein. Therefore, we avoided the use of 
overexpression approaches and instead focused our analysis on studying the effects 
of loss-of-function of the endogenous protein. 
 
5.4 EMT and the cancer stem cell phenotype  
 
Accumulating evidence over the last years demonstrates a link between the transition 
from an epithelial to a mesenchymal state and the acquisition of stem cell traits in 
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cancer cells. Especially the outgrowth of metastases is closely connected to EMT 
through the generation of more motile cancer cells that invade and disseminate to 
distant sides. A prerequisite to initiate the growth of cancer cells outside and far away 
from the primary tumour is the gain of cancer stem cell traits or tumour initiating 
abilities in particular the ability to self-renew, to generate progeny and to act as 
founder cells for the formation of micro-and macro-metastasis. 
Previously it was discovered that the induction of a mesenchymal state is associated 
with the induction of a stem cell state in both normal epithelial cells and in 
carcinomas (Mani et al., 2008). That leads to the assumption that cancer cells take 
advantage of the conserved EMT cellular program to achieve dissemination and 
acquire phenotypes that are beneficial for tumour progression. In breast cancer, it 
was shown that tumours harbour cell populations with stem-cell characteristics. It is 
possible to distinguish this population from the rest of the tumour cells through the 
expression of the surface proteins CD44 and CD24. The stem cell population is 
characterised by the expression pattern CD44high/CD24low. Importantly, this 
subpopulation expresses markers associated with EMT, like reduced E-cadherin 
expression, higher expression of N-cadherin, vimentin and fibronectin. In addition, the 
EMT regulators Snail, Twist and FOXC2 (forkhead box protein 2) are induced in this 
particular cell population (Mani et al., 2008). 
A strong connection between EMT and CSCs is suggested by the discovery that the 
same transcriptional regulators are involved in the control of both features. Zeb1 
negatively regulates the expression of the members of the miR-200 family, which 
function to suppress stemness (Burk et al., 2008; Korpal et al., 2008; Park et al., 
2008). Furthermore, miR-200 family members have been shown to suppress the 
expression of the Bmi-1, component of the polycomb complex 2, which is known to 
be important to support the stemness in cancer and embryonic stem cells (Shimono 
et al., 2009; Wellner et al., 2009). 
Pathways that are known to participate in self-renewal or stem cell maintenance were 
also reported to directly influence EMT regulators. For example the Wnt-β-catenin 
pathway is strongly activated at the invasive front of colorectal cancer where the cells 
undergo EMT (Brabletz et al., 1998). These and many other studies suggested that 
Wnt signalling is involved both in the induction of EMT and in the generation of CSCs 
(Schmalhofer et al., 2009). Additionally, this pathway is important for regulating the 
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turnover and activity of Snail in breast cancer (Yook et al., 2005) and normal 
hepatocellular regeneration (Sekiya and Suzuki, 2011). Especially TGFβ, as a major 
EMT inducer (Kalluri and Weinberg, 2009; Massague, 2008), activates Snail, Slug 
and Twist in many epithelial cancers and induced the stem cell population 
CD44high/CD24low in immortalised mammary epithelial cells (Thuault et al., 2006).  
 
5.4.1 The role of Snail and Slug in the maintenance of cancer stem cells in GBM 
 
In non-epithelial cancers like GBM little is known about the role of EMT or GMT in the 
induction and maintenance of CSCs. In the last few years some evidence arose that 
a comparable connection, involving similar components and pathways also exists in 
glioma. Especially TGFβ signalling seems to play a major role in GBM both for the 
induction of EMT and the maintenance of stem-cell properties (Anido et al., 2010; 
Ikushima et al., 2009; Penuelas et al., 2009). Recently it was shown that the EMT 
regulator Zeb1 controls key features of CSCs in glioma and can be used as a marker 
for invasive cells that is also linked to chemoresistance (Siebzehnrubl et al., 2013). 
Furthermore, the EMT marker TWIST1 is involved in the promotion of invasiveness 
and stemness of glioma cells (Mikheeva et al., 2010). There are also a few reports 
showing that Snail and Slug can induce cellular changes comparable to EMT and 
that the loss of theses transcription factors reduces invasion and vimentin expression 
(Han et al., 2011; Myung et al., 2014; Yang et al., 2010). However, a direct 
connection of GMT regulators of the Snail family to the CSC phenotype has been 
missing so far. 
In our study we were able to show and confirm a direct link of the transcription factors 
Snail and Slug to GMT and stem-cell features in GBM. The loss of Snail or Snail and 
Slug impairs not only the transition from a glial to a mesenchymal cell state induced 
by TGFβ signalling but also the ability of cells to self-renew as functionally shown 
with a glioma sphere formation assay in two GBM cell lines (see Fig. 4.9). Also, the 
expression of the established glioma stem cell markers SOX2, OCT4, MAML3 and 
CD15 is impaired by silencing Snail and Slug (see Fig. 4.8). These results are clearly 
arguing for a connection of GMT and the induction of a CSC phenotype in glioma.  
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Surprisingly, we were not able to detect a reduction of the commonly used glioma 
stem cell marker CD133 upon silencing Snail and Slug; indeed silencing of the two 
transcription factors led to an induction of CD133 (data not shown). These findings, 
however, are supported by a very recent report, which analysed co-expression of 
glioma stem cell markers in publicly available GBM databases. This study found that 
CD133 is negatively correlated with CD44 and in turn CD44 is positively correlated 
with the stem cell marker CD15. Moreover, the expression of CD133 overlapped 
surprisingly with the proneural signature of the samples, whereas CD44 and CD15 
clearly overlapped with the mesenchymal phenotype (Brown et al., 2015). This could 
mean that CD133 is not a suitable marker for stem cell traits induced via GMT and 
could explain our observations. 
 
5.5 Invasion in GBM 
 
GBM is the most aggressive tumour type of the CNS and most brain tumours are 
glioblastomas. With a median survival of fifteen month, patients have a very poor 
prognosis. Despite the development of improved imaging methods, specific surgical 
techniques and new chemo-and radiotherapies the survival prognosis for patients did 
not significantly change in the last decades. One of the mayor reasons is the high 
infiltration of GBM cells throughout the brain, often even to the opposite hemisphere. 
Upon surgical removal of the primary tumour it is nearly impossible to remove all 
tumour tissue. Many patients suffer from a relapse with secondary tumours formed by 
residing invasive cancer cells. Interestingly, therapeutic approaches, such as anti-
angiogenic treatment to withdraw oxygen and nutrients from the tumour result in an 
initial shrinkage of the tumour but enhances the invasiveness of the cells. 
It is not fully understood which mechanisms are responsible for the high invasive 
capacity of GBM. One explanation could be EMT/GMT. The gain of mesenchymal 
features is in many cancer types closely connected with a higher invasiveness of the 
cells and a further progression of the disease. Snail and Slug as the major regulators 
of EMT were shown to have a strong influence on invasion in epithelial cancers. 
Therefore, studying GMT and invasion in glioma is very important for understanding 
the mechanisms for the enhanced invasiveness of the cells, which may lead to an 
improved treatment for patients. 
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5.5.1 GMT and invasion 
 
In glioma many recent reports showed a connection between EMT/GMT regulators 
and the invasive capacity of the glioma cells in vitro. In this study we also examined 
the influence of Snail and Slug on the invasiveness of glioma cells in vitro and in vivo. 
Interestingly, we found that the precise extent to which GBM cell invasion depended 
on specific members of the Snail family was cell line dependent. In the modified 
Boyden chamber assay the primary cell line GBM046x showed that silencing of Snail 
is sufficient to abrogate the ability of the cells to invade through the matrigel layer. 
Surprisingly, silencing of Slug alone led to a significant increase of invasion, 
suggesting a differential role of these two transcription factors in regulating invasive 
behaviour in this cell line. When both regulators were lost the invasive capacity of the 
cells was again significantly reduced (see Fig. 4.11). The same results were obtained 
for GBM046x with a second invasion assay that mimics the three dimensional tumour 
architecture and allows gliomaspheres to invade a collagen layer in all directions (see 
Fig.4.12).  
In the established cell line G55 the single knock-down of Snail or Slug had no 
significant effect on the invasion of the cells, either in the matrigel invasion assay or 
in the collagen invasion assay. Only the loss of both regulators led to a significant 
decrease of invasiveness in both assays (see Fig. 4.11; 4.12). These findings show 
that Snail alone can already influence the invasive behaviour in a cell line dependent 
manner, but taking into account that only the double knockdown of Snail and Slug 
shows a complete transition from proneural to mesenchymal state in terms of 
signature gene expression our data support a model in which both regulators can 
play a crucial role in GMT induced invasion. Therefore we performed in vivo studies 
with glioma cells lacking Snail and Slug and examined the invasiveness of those cells 
directly in the brain. We could observe that the loss of Snail and Slug led to severely 
decreased parenchymal invasion compared to the control cells. It should also be 
pointed out that some of our markers to determine the state of the cells (proneural or 
mesenchymal) are also functionally involved in invasion. The cadherin CDH11, as 
described in section 5.2, is strongly involved in glioma invasion and its loss results in 
decreased invasion. CD44 is not only a mesenchymal marker but also an adhesion 
molecule of the cells to the ECM. In this particular case, the amount of CD44 protein 
may be more important for determining the mesenchymal state of the cells than for 
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showing a direct connection to the invasive behaviour of the cells because to 
enhance the invasion of cells CD44 has to be cleaved by ADAM proteases (Nagano 
et al., 2004; Okamoto et al., 1999). To further study if also the cleavage of CD44 is 
impaired in Snail and Slug silenced cells one could examine the activity of ADAM 10 
and 11a. 
In general, additional potential avenues for the further elucidation of the connection 
between GMT and invasion could involve analysis of the expression levels of genes 
and proteins closely connected to invasion mechanisms of glioma. For example one 
could characterise the expression of MMPs or integrinβ1, in particular in tumour 
samples from our in vivo studies. 
 
5.6 Snail and Slug in tumour growth 
 
A major part in the study presented here is the assessment of the role of Snail and 
Slug in glioma tumour growth. So far this topic is underrepresented in the published 
reports. Many of the reports mentioned in section 3.3.3 or 5.4.1 showed no in vivo 
data to confirm their findings about the role of Snail and Slug (Han et al., 2011) 
(Myung et al., 2014) (Dong et al., 2014). The rest of the reports often used only 
subcutaneous injection into mice and no orthotopic intracranial injections into the 
brain. The biggest limitation here is that important components of the specific 
microenvironment of the brain are missing so that the subcutaneous tumour model 
cannot fully mirror the natural situation of brain tumour growth. If intracranial 
injections were used, the authors only analysed the survival of the mice and did not 
analyse tumour volume or other features influencing tumour growth, such as 
invasion, proliferation, apoptosis or vascularisation (Yang et al., 2010) (Savary et al., 
2013). Nevertheless, these key features of tumour growth and progression need to 
be assessed to fully understand the role of Snail and Slug in glioma growth. 
Therefore, we performed intracranial orthotopic injections into the brains of mice to 
have a microenvironment comparable with situation in GBM. In these in vivo 
experiments we assessed the proliferation, apoptosis and the vascularisation of the 
tumours by immunofluorescence staining. By analysing the volume of the tumours we 
saw a striking effect of silencing of Snail and Slug. The loss of both transcription 
factors led to significantly reduced tumour growth (see Fig. 4.13). Surprisingly, we 
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could not observe any differences in proliferation, apoptosis and vascularisation of 
the Snail/Slug silenced and control tumours (see Fig. 4.14-16), indicating that Snail 
and Slug have no major influence on these key features of tumour growth. These 
results were also confirmed by analysing the proliferation and apoptosis of glioma 
cells in vitro (see Fig. 4.10). By contrast, analysis of the invasiveness of the tumours 
obtained from the in vivo experiments showed that the invasive capacity of the glioma 
cells is severely impaired when Snail and Slug are silenced (see Fig.4.17). 
Interestingly, the abrogated invasiveness of Snail/Slug silenced tumours seems to be 
the main reason of the reduced tumour growth. We were also able to confirm these 
data with two independent in vitro invasion assays (see Fig. 4.11; 4.12). Thus, our 
work shows for the first time the connection between Snail and Slug and in vivo 
invasiveness of glioma cells. 
 
5.7 Perspectives 
5.7.1 Transcriptomic analysis 
 
To further confirm the specific role of Snail and Slug in GBM and in particular in the 
molecular subtype transition that possibly occurs also during the progression of the 
disease in patients, a transcriptome analysis could be a helpful approach. We are 
currently generating Snail and Slug loss-of-function glioma cells with the 
CRISPR/Cas9 technique. In collaboration with the German Cancer Research Center 
(DKFZ) in Heidelberg, we will analyse the changes in the transcriptome following the 
loss of Snail and Slug, which could further support the role of Snail/Slug in GMT by 
demonstrating a shift of the expression signature to a proneural one. This analysis 
may also allow us to gain a deeper insight into the Snail/Slug-dependent 
mechanisms of GMT, invasion and stemness in glioma. Furthermore, it could also 
complement the panel of markers we are currently using to determine GMT and the 
CSC phenotype. Such an approach can also provide important information about 
pathways and mechanism that could be used as potential therapeutic targets to act 
directly on Snail and Slug expression or on the downstream pathways controlled by 
them to prevent GMT and the gain of a more aggressive phenotype in glioma cells.  
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5.7.2 Snail and Slug as therapeutic targets   
 
In general, transcription factors are challenging drug targets. Nevertheless, there are 
first attempts to target EMT factors with some initial success. Few chemical 
compounds act directly on Snail, a more promising approach seems to be the 
targeting of pathways regulating Snail expression (e.g. through HDAC (histone-
deacetylase) or LSD (lysine-specific-demethylase) inhibitors) or the interaction of 
Snail with E-cadherin or p53 (Fig.5.1) (Kaufhold and Bonavida, 2014). 
 
 
Fig. 5.1 Chemical inhibitors of Snail-induced EMT (taken from Kaufhold et al., 2014) 
 
Other EMT regulators are also affected by inhibition of HDACs. The class I HDAC 
inhibitor mocetinosat acts on the chemotherapy resistance of colorectal tumours 
expressing high levels of ZEB1. Mocetinosat acts on the ZEB1 target gene miR203 
(a major drug sensitizer repressed by ZEB1) as an epigenetic drug to restore miR203 
expression, repress stemness and re-induce sensitivity against standard 
chemotherapy (Meidhof et al., 2015). Epigenetic reactivation of miR expression is 
technically easier to realize than a targeted delivery of miRNAs directly to a tumour. 
Comparable strategies could be helpful also for the treatment of GBM. In glioma it 
was recently shown that in multi-drug resistant cells, which had undergone GMT, 
ectopic expression of miR203 reversed the resistance phenotype by the 
downregulation of Slug. Unfortunately, the effects on Snail following overexpression 
of miR203 were not assessed (Liao et al., 2015). Collectively, this work combined 
with a transcriptome analysis, as described above, for getting a better understanding 
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of the mechanisms and pathways regulated by Snail and Slug, has an important 
potential for new approaches for the design of therapeutic strategies against 
Snail/Slug-induced GMT, invasion and stemness.  
 
 
Fig. 5.2 Graphical summary TGFβ1 induced GMT via Snail and Slug leads to an invasive 
phenotype, CSC maintenance and tumour propagation. 
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6. Materials and Methods 
 
6.1 Materials 
 
6.1.1 Antibiotics 
 
Name Stock concentration Final concentration 
Ampicillin (#A-9518, 
Sigma) 
100 mg/ml in aqua dest. 100 µg/ml 
Kanamycin (#T832.1, 
Roth) 
100 mg/ml in aqua dest. 100 µg/ml 
Table 6.1 Antibiotics for selection of bacterial cells 
Name Stock concentration Concentration for 
maintenance of 
transgene expression 
Blasticidin (#R210-01, 
Invitrogen) 
6 mg/ml in PBS 6 µg/ml 
Puromycin (#P9620, 
Sigma-Aldrich) 
10 mg/ml ready to use 
solution 
G55: 4 µg/ml 
GBM46x: 0.4 µg/ml 
Table 6.2 Antibiotics for selection of mammalian cells 
 
6.1.2 Antibodies 
 
6.1.2.1. Primary antibodies 
 
Antigen Species Dilution Company 
Snail Rat (monoclonal) 1:500 for WB #4719, Cell 
Signaling 
Slug Rabbit 
(monoclonal) 
1:500 for WB #9585S, 
Cell Signaling
  
Materials and Methods 
64 
 
CD133 Mouse 
(monoclonal) 
1:500 for WB #130-092-395, 
Miltenyi  
CD44 Mouse 
(monoclonal) 
1:5000 for WB #3570S,     
Cell Signaling
  
YKL40 Goat (polyclonal) 1:200 for WB #AF2599,  
R+D Systems
  
Olig2 Rabbit (polyclonal) 1:1000 for WB #18953,    IBL
  
T-cadherin Mouse 
(monoclonal) 
1:1000 for WB #SC166875,  
Santa Cruz  
MAP2 Mouse 
(monoclonal) 
1:1000 for WB #M9942, Sigma 
ASPHD2 Rabbit (polyclonal) 1:500 for WB #HPA000820 
,Sigma 
Tubulin Mouse 
(monoclonal) 
1:8000 for WB #DLN09992, 
Dianova  
Table 6.3 Primary antibodies for western blots 
 
Antigen Species Dilution Company 
Endomucin Rat (monoclonal) 1:500 #14-5851, 
eBioscience 
Phospho-histone 3 rabbit 1:200 #IHC-00061,  
Bethyl lab 
BrdU Mouse 
(monoclonal) 
1:200 #M0744,  
Dako Cytomation 
Human nuclei Mouse monoclonal 1:500 #MAB4383, 
Millipore 
Table 6.4 Primary antibodies for stainings 
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6.1.2.2. Secondary antibodies 
 
Antigen Dilution Company 
Peroxidase-conjugated 
AffiniPure goat anti rabbit 
IgG 
1:2500 for Western Blot #111-035-144, Dianova 
Peroxidase-conjugated 
AffiniPure donkey anti 
goat IgG 
1:2500 for Western Blot #705-035-147, Dianova 
Peroxidase-conjugated 
AffiniPure goat anti mouse 
IgG 
1:2500 for Western Blot #115-035-146, Dianova 
Peroxidase conjugated 
f(ab’)2 fragment goat anti 
rat IgG 
1:2500 for Western Blot #721-1333, Rockland 
Alexa Fluor®568 goat anti 
rat IgG 
1:200 for 
Immunofluorescence 
staining 
#A11077, Life 
Technologies 
Alexa Fluor®568 goat anti 
rabbit IgG 
1:200 for 
Immunofluorescence 
staining 
#A11036, Life 
Technologies 
Alexa Fluor®568 goat anti 
mouse IgG 
1:200 for 
Immunofluorescence 
staining 
#A11031, Life 
Technologies 
Table 6.5 Secondary antibodies 
 
6.1.3 Human cell lines 
 
LN-229x: human glioblastoma cell line  
G55: established human glioblastoma cell line  
GBM10: primary glioblastoma cell line, isolated from human tumour material 
GBM18: primary glioblastoma cell line, isolated from human tumour material 
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GBM37x: primary glioblastoma cell line, isolated from human tumour material  
GBM46x: primary glioblastoma cell line, isolated from human tumour material  
HEK293T: human embryonic kidney cell line: This cell line is transformed with 
sheared human adenovirus type 5 DNA. The E1A adenovirus gene is expressed in 
these cells and participates in the transactivation of some viral promoters allowing the 
cells to produce large amounts of viral particles when transfected with suitable 
plasmids. This cell line was purchased from Invitrogen. 
 
6.1.4. Knock-down cell pools generated in this work 
 
Name Construct/Lentivirus MOI Selection 
G55 nsc  non silencing control 
(Thermo Scientific) 
80 Puromycin 
G55 shSlug pGIPZ-shSlug #2 
( Thermo Scientific) 
80 Puromycin 
G55 shSnail pGIPZ-shSnail #19 
(Thermo Scientific) 
80 Puromycin 
G55 
shSnail/shSlug 
pGIPZ-shSnail #19/ 
pGIPZ-shSlug #2 
(Thermo Scientific) 
Each 40 Puromycin 
GBM46x nsc non silencing control ( 
Thermo Scientific) 
10 Puromycin 
GBM46x shSlug pGIPZ-shSlug #2 
( Thermo Scientific) 
10 Puromycin 
GBM46x shSnail pGIPZ-shSnail #19 
(Thermo Scientific) 
10 Puromycin 
GBM46x 
shSnail/shSlug 
pGIPZ-shSnail #19/ 
pGIPZ-shSlug #2 
(Thermo Scientific) 
Each 5 Puromycin 
Table 6.6 Generated knock-down cell pools 
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6.1.5. Plasmids 
 
pCL-VSV-G lentiviral packaging plasmid, expresses the envelope protein 
glycoprotein-G (#1733 Addgene, Garry Nolan) 
pS-PAX2 lentiviral packaging plasmid (#12260 Addgene, Didier Trono) 
pGIPZ non silencing control (Delic et al.) lentiviral expression vector (non 
targeting) 
Hairpin sequence nsc (non silencing control):  
TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACA
GATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA 22mer sense: 
ATCTCGCTTGGGCGAGAGTAAG22merantisense: TACTCTCGCCCAAGCGAGAG 
 pGIPZshSnail mir (human) lentiviral expression vector to silence SNAI1 
Hairpin sequence shRNA Snail (V2LS_199873) 
 
TGCTGTTGACAGTGAGCGCAAAGGTACACTGGTATTTATATAGTGAAGCCACAG
ATGTATATAAATACCAGTGTACCTTTATGCCTACTGCCTCGGA 
 
pGIPZ shSlug mir (human) lentiviral expression vector to silence SNAI2 
Hairpin sequence ShRNA Slug (V2LHS_153126) 
TGCTGTTGACAGTGAGCGACGAAGCCAAATGACAAATAAATAGTGAAGCCACAG
ATGTATTTATTTGTCATTTGGCTTCGGTGCCTACTGCCTCGGA 
Hairpin sequence color code: miR-30 derived sequence, mature sense, loop, mature 
antisense, miR-30 derived sequence (as given from the manufacturer) 
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6.1.6 Sequences (Primers) 
 
CDH11  
forward:TGGGCGGACTCTCAGGGACA  
reverse: TTCCTCCCCAGGGACGGCTG 
T-cadherin  
forward: AGCGATGGCGGCTTAGTTG  
reverse:CCCCGACAATCACGAGTTCTG 
 
CD44 
forward: TGGCACCCGCTATGTCCAG 
reverse: GTAGCAGGGATTCTGTCTG  
 
MAML3 
forward: CAGCAGGTCAATCAGTTTCAAG 
reverse: GGTTCTGGGAGGGTCCTATTC 
 
OCT4 
forward: GCTCGAGAAGGATGTGGTCC 
reverse: CGTTGTGCATAGTCGCTGCT 
 
SOX2 
forward: GCCGGCGGCAACCAGAAAAACAG 
reverse: CCGCCGGGGCCGGTATTTAT 
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HPRT1 (housekeeping gene) 
forward: TATGGCGACCCGCAGCCC 
reverse: GCAAGACGTTCAGTCCTGTCCAT 
 
6.1.7 Growth factors 
 
Reagent Stock concentration Final concentration 
EGF (epidermal growth 
factor)  
(#C-10015-SS Peprotech) 
200 µg/ml 20 ng/ml 
bFGF (fibroblast growth 
factor)  
 (#C-10018-BF Peprotech) 
200 µg/ml 20 ng/ml 
TGFβ1 (transforming 
growth factor β1) (-21C 
Peprotech) 
10 mg/ml 2.5 ng/ml 
Table 6.7 Growth factors 
 
6.1.8 Protein/DNA ladders 
 
6.1.8.1 Protein ladders 
 
For proteins with low molecular weights PageRuler Prestained Protein ladder 
(#26616, Thermo Scientific) was used. 
For proteins with high molecular weights Spectra Multicolor High Range Protein 
ladder (#26625, Thermo Scientific) was used. 
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6.1.9 Media, Buffers and other reagents 
6.1.9.1 Animal experiments 
 
Anaesthesia: 9 ml 0.9 % NaCl solution, 2 ml ketamine 10% (#FS1670041 bela-
pharm GmbH), 0.5 ml xylazine 2 % (CEVA Tiergesundheit GmbH) 
4% Paraformaldehyde: 80 g PFA were solved in aqua dest. 
0.5M PB pH7.4: 115 mM NaH2PO4 x H2O, 385 mM Na2PO4 x H2O., pH was adjusted 
to 7.4 
Cryoprotection solution (CPS): 500 ml 0.1 M PB (pH 7.4), 250 ml Ethylene glycol 
(#9516.1, Roth) and 250 ml Glycerol (#3783.1, Roth), solution was stored at RT 
30% sucrose in 0.1M PB pH7.4: 0.1 M D (+)-Sucrose (#84099, Fluka), solution was 
sterile filtered and stored at 4 °C 
 
6.1.10 Bacterial cultures 
 
LB-Agar: 32 g  of ready to use powder were dissolved in 1l aqua dest., the solution 
was autoclaved at 121 °C for 15 min, cooled down to 40-50 °C and the appropriate 
antibiotics were added. Afterward the LB-Agar was poured into 10 cm dishes. The 
plates were stored at 4 °C. 
LB-Medium: 20 g of LB powder were dissolved in 1 l aqua dest., and autoclaved at 
121 °C for 15 min. The medium was stored at 4 °C. 
 
6.1.11 Cell culture 
 
Accutase: #A11105-01 Gibco 
2.5M CaCl2: dissolved in aqua dest., sterile filtered and stored at 4°C 
10mM Chloroquine: dissolved in aqua dest., sterile filtered an stored at 4°C 
CO2-independent Medium without L-Glutamine: #18045-054, Gibco 
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Cryo-Medium SFM: #C-29910, Promocell 
Dimethyl sulfoxide (DMSO): #A994.1, Roth 
D-MEM/F12 (1:1) (with GlutaMAX): #31331-028, Gibco 
D-MEM (Dulbecco´s Modified Eagle Medium High Glucose (with GlutaMAX, 4.5 
g/l D-Glucose, Sodium Pyruvate): #31966-021, Gibco 
FCS (Foetal Calf Serum): # 10270-106, Gibco 
General cell culture medium for adherent cells: 500 ml DMEM, 10 %FCS 
2xHBS: 281 mM NaCl2, 100 mM HEPES, 1.5 mM Na2HPO4 in aqua dest., pH 7.12, 
sterile filtered and stored at -20°C 
HEPES: #1563-056 Gibco 
Tumoursphere medium: 500 ml DMEM/F12, 10ml B27 serum-free supplement 
(#12587-010, Gibco), 5 ml amphotericin B (#A2942, Sigma), 2.5 ml 1M HEPES, 0.5 
ml gentamicin (50 mg/ml) (P11-005, PAA Laboratories GmbH) 
1xPBS: #10010-056, Gibco 
Polybrene: 6 mg/ml in aqua dest., sterile filtered and stored at -20 °C 
Poly (2-hydroxyethyl methacrylate) (pHEMA): 10 mg/ml pHEMA (#P3932-25g, 
Sigma-Aldrich) was dissolved in 95 % ethanol, sterile filtered and stored at RT 
Trypsin/EDTA: #L11-004, PAA Laboratories GmbH 
Collagen solution (10 ml): 5.1 ml bovine collagen (Biomatrix), 3.5 ml TSM, 1.36 ml 
HEPES 
FACS Staining buffer: 1x PBS, 0.5 % BSA, 2 mM EDTA, pH 7.2 
Papain stock solution: 100 mg papain (LS004194; Worthington) in 5 ml EBSS 
(14155.048, Invitrogen) 
DNase I solution: 100 mg DNase I in 5 ml sterile 0.15 M NaCl, stored in 50 µl 
aliquots at -20 °C (#DN25-100mg, Sigma) 
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Solution 1 for primary cell isolation: 50 ml HBSS (#14180-046, Invitrogen) , 9 ml 
D-Glucose (300 mg/ml), 7.5 ml 1 M HEPES; adjust pH to 7.5, fill up with H2O to 500 
ml; activate before use 30 min at 37 °C, add freshly 200 µl papain and 50 µl of 
DNase I solution 
Solution 2 for primary cell isolation: 100 ml solution 1, 70 mg collagenase I 
(LS004194, Worthington), 70 mg hyaluronidase (#H3884-100mg, Sigma), 100 mg 
trypsin (#T9935-100mg, Sigma), stored at -20 °C in 5 ml aliquots, add freshly 50 µl 
DNase I solution 
 
6.1.12 Western Blot  
 
Ammonium persulfate (APS): 1 g of powdered APS solved in 100 ml aqua dest. 
and stored in 1 ml aliquots at -20 °C (9592.1, Roth) 
Lower-buffer: 0.5 M Tris base, set pH to 8.8, add 0.4 % SDS, fill up with H2O 
Lysis buffer (Laemmli): 10 mM Tris HCl, 2 % SDS, 2 mM EGTA, 20 mM NaF, filled 
up with aqua dest. 
Blocking buffer: 5 % milk powder in 1x PBS-Tween-20 (0.1 %) 
20x PBS: 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4x2 H2O, 1.8 mM KH2PO4, 
filled up with aqua dest., set pH to 7.4 
10x Running buffer: 250mM Tris base, 2M glycine, 1% SDS, filled up with aqua 
dest. 
Sample buffer: 40 ml 10 % SDS, 16 ml 1 M Tris pH 6.8, 20 ml glycerol, 19 ml aqua 
dest., stored in 800 µl aliquots, for usage mixed with 200 µl 1% bromphenol blue and 
50 µl β-mercaptoethanol 
8% separating gel: 2.7 ml 30 % poly-Acrylamide, 2.6 ml lower buffer, 4.5 ml aqua 
dest., 100 µl APS (10%), 10 µl TEMED 
12% separating gel: 4 ml 30 % poly-Acrylamide, 2.6 ml lower buffer, 3.5 ml aqua 
dest., 100 µl APS (10 %), 10 µl TEMED 
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Stacking gel: 0.65 ml 30 % poly-Acrylamide, 1.3 ml upper buffer, 4.5 ml aqua dest., 
100 µl APS (10 %), 10 µl TEMED 
TEMED: Tetramethylenediamine #A1148, Applichem 
10x Wet Transfer buffer without SDS: 200 mM Tris base, 1.5 M glycine, filled up 
with aqua dest. 
Upper buffer: 0.5M Tris base, 0.4 % SDS, filled up with aqua dest. 
Stripping buffer: 200 mM glycine, 0.05 % Tween-20, filled up with aqua dest. 
Washing buffer (PBS-T): 1x PBS, 0.1 % Tween-20, filled up with aqua dest. 
 
6.2 Solvents/Chemicals 
 
Solvents and chemicals were, if not mentioned differently, purchased from Sigma-
Aldrich, Roth, Merck and Applichem 
 
6.3 Methods 
6.3.1 Working with RNA 
6.3.1.1 RNA extraction 
 
Cells were plated in 10 cm dishes (800.000-1.000.000 cells, depending on the 
duration of the experiment). Cells grown as spheres were centrifuged and washed 
with PBS afterwards the cells were lysed with 350 µl RLT buffer (RNeasy Mini Kit, 
#74106, Qiagen; 1 ml RLT buffer+10 ml beta-mercaptoethanol). Cells grown 
adherent were washed with PBS and lysed with 350 µl RLT buffer and scraped off 
the dish with a cell lifter RNA extraction was performed following the manufacturer’s 
instructions of the Qiagen RNeasy Mini Kit. The optional on-column DNase digestion 
was performed using the RNAse-Free DNase Set (#79254, Qiagen) in order to 
remove residual DNA. The concentration of the RNA was determined by NanoDrop 
(Peqlab) photometric measurement at a wavelength of 260 nm.  
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6.3.1.2 Reverse transcription 
 
1 µg of RNA filled up with DEPC-water to 11 µl together with 1 µl random hexamer 
were incubated for 5 min at 70 °C and cooled down immediately on ice. This 
procedure unfolds the secondary structures of the RNA. 7 µl of a mix containing 4 µl 
5x reverse transcriptase reaction buffer (#EP0451,Thermo), 2 µl dNTP-Mix (10 mM) 
(#NO447L, NEB) and 1 µl RNase-Inhibitor (#03335402001, Roche) were added and 
the whole mixture was centrifuged briefly followed by an incubation of 5 min at RT. 1 
µl of Revert Aid H Minus M-MuLV Reverse transcriptase (#EP0451, Thermo) was 
added the whole reaction centrifuged briefly and incubated for 10 min at RT followed 
by 60 min incubation at 42 °C. The enzymatic reaction was inactivated for 10 min at 
70°C. The mixture was cooled down on ice and 1 µl RNase H (#10786357001, 
Roche) was added. Again the reaction was centrifuged and incubated for 20 min at 
37 °C. The cDNA was diluted with 180 µl DEPC-water.  
 
6.3.2 Working with DNA 
6.3.2.1 Plasmid isolation 
 
The isolation of larger amounts of plasmid was carried out according to the protocol 
of the Isolation Kit PureLink HiPure Plasmid Maxiprep Kit (#K2100-07, Invitrogen)  
 
6.3.2.2 Measuring DNA/RNA concentrations 
 
Concentration of DNA or RNA was measured with NanoDrop (Peqlab) at a 
wavelength of 260 nm. 
 
6.3.2.3 Sequencing 
 
All sequencing reactions were performed by SeqLab. 
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6.3.2.4 Quantitative real time polymerase chain reaction (qRT-PCR) 
 
Quantitative real time PCR allows amplification and simultaneously quantification of 
the amount of DNA/cDNA molecules of interest in the sample either as absolute 
number of copies or as relative amount to a normalizing gene. Quantification is based 
on the detection of fluorescent signals, which are produced during PCR cycles. In this 
work the SYBR Green method was used. The fluorescent dye SYBR green 
intercalates with double- stranded DNA and emits light when excited. The PCR 
reactions were performed with the Absolute QPCR SYBR Green ROX Mix (ABgene # 
AB-1162/a) on a StepOne Plus system (ABgene, Thermo-Scientific). 
Reactions were performed in triplicates with 20 ng of cDNA, 100 nM forward (fw) 
primer, 100 nM reverse (rev) primer, 12,5 µl 2X ABsolute™ QPCR SYBR Green Mix 
and DEPC-water. in a total volume of 25 µl. The amount of target mRNA was 
determined using the comparative cycle threshold method and normalized relatively 
to the amount of the housekeeping HPRT mRNA. 
 
Step Temperature Time Number of cycles 
Enzyme activation 95°C 15 min 1 
Denaturation 95°C 30 sec 45 
Annealing 60°C 30 sec  
Extension 72°C 30 sec  
Denaturation 95°C 1 min 1 
Annealing/Extension 60°C 1 min 1 
Melt curve 55°C 15 sec 0.5°C stepwise 
increse in 
temperature 
End 4°C hold  
Table 6.8 Routinely used qPCR program. 
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6.3.3 Working with proteins 
6.3.3.1 Protein extraction 
 
Plates with adherent cells were placed on ice and washed with cold PBS. After 
aspiration of all PBS the cells were lysed with 100-250 µl Laemmli-buffer (see section 
6.1.12) and scraped off the dish with a cell scraper. The proteins were collected in 
Eppendorf-cups.  
Cells grown as spheres were span, washed with cold PBS. After aspiration of all PBS 
the cell pellet was resuspended in 80-200 µl Laemmli-buffer. The proteins were 
collected in Eppendorf-tubes. Proteins were stored at -20 °C. 
 
6.3.3.2 Determination of protein concentration 
 
The concentration of proteins was determined with the colorimetric DC Protein Assay 
Reagents Package (#500-01116, BIO-RAD). The main principle behind this method 
is a combination of the reactions of copper ions with the peptide bonds under alkaline 
conditions (the Biuret test) with the oxidation of aromatic protein residues which leads 
to colour development which can be determined by absorbance measurement 
between 650 and 750 nm. Protein concentration was determined using the 
colorimetric DC Protein Assay Reagents Package (BIO-RAD # 500-0116). The 
alkaline copper tartrate solution (Reagent A), the diluted Folin Reagent (Reagent B) 
and Reagent S were prepared according to the manual. In an ELISA plate 25 μl of 
the mixture of reagent B and S were added to the sample (5 μl of protein lysate) and 
combined with 200 µl reagent B. After 15 min incubation at RT absorbance was 
measured at 750 nm in a plate reader. Pure Laemmli buffer was measured as a 
blank. The protein concentration was determined using a calibration curve measured 
with increasing concentrations of BSA (bovine serum albumin). Afterwards sample 
buffer (see section 6.1.12) was added to the protein lysate in a ratio 1:3 and the 
sample heated at 95 °C for 5 min to denature the proteins.  
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6.3.3.3 SDS-PAGE (Sodium-Dodecyl-Sulfate-Poly Acrylamide Gel 
Electrophoresis)/Western Blot   
 
The principle behind this method lies in separation of proteins according to their size. 
Due to binding of SDS, proteins have identical charge per unit mass, which leads to a 
size depending fractionation.  Electrophoresis was carried out by standard 
discontinuous SDS-polyacrylamide denaturing gel electrophoresis in Mini-Protean 
Tetra cells (BIO-RAD). Depending on the size of the protein being analysed 8 % or 
12 % separating gels were prepared (see section 6.1.12). Separated proteins were 
transferred electrophoretically to PVDF membranes (Hybond ECL, Amersham) at 
100 mA per gel for 2 h using the Wet Blot System from BioRad. Membranes were 
incubated for 1 h in 5 % milk blocking buffer (PBS, 0.1 % Tween-20, 5 % milk 
powder) to prevent unspecific antibody binding followed by primary antibody 
incubation in the blocking buffer at 4°C overnight. Blots were rinsed 3 times (15 min 
each) in washing buffer (PBS, 0.1 % Tween 20) and incubated for 1 h at RT with the 
appropriate secondary HRP-conjugated antibody diluted in blocking buffer. After 
three times washing with washing buffer and once with PBS (each 15 min), 
chemiluminescent signal was produced using ECL Western Blotting Detection 
System (Thermo Scientific), ECL plus System (Perkin Elmer) or ECL Pico/Femto 
System (Thermo Scientific) depending on the abundance of the protein and 
peroxidase activity of the secondary antibody. The membrane was put into a 
developing cassette and the luminescent signals developed on a radiographic film 
(Thermo Scientific) with exposure times of 1 sec to 1 h, depending on the signal 
strength. 
 
6.3.3.4 Western blot membrane stripping 
 
To re-incubate the membrane with another primary antibody, the membrane was 
incubated in stripping buffer (see section 6.1.12) for 1 h at RT and subsequently 
blocked with 5 % blocking buffer (see section 6.1.12) again for 1 h. Then the new 
primary antibody was added and incubated over night at 4 °C. The rest of the 
procedure was carried out as described above. 
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6.4.4 Cell culture 
6.4.4.1. Isolation of primary glioblastoma cells from human tumor specimen 
 
To isolate and culture primary glioblastoma cells from human tumor specimen the 
following detailed protocol was used (based on (Seidel, 2015 #226)). All steps of the 
tissue dissociation were carried out under sterile conditions in a laminar flow cell 
culture hood to reduce the risk of contamination of the primary culture. 
For tissue dissociation and cell isolation the tumour specimen was transferred to a 
sterile petri dish using autoclaved forceps and washed with PBS 2 times. Hereafter 
the tissue was cut into small fragments using a sterile scalpel. The fragments were 
further chopped with a sterile single edged razor blade until the tissue was well 
minced. The tumour tissue was transferred to a sterile 15 ml tube by flushing the dish 
with 5 ml activated Dissociation medium 1 and pipetting it with a sterile pipette. The 
tissue suspension was incubated at 37 °C for 30 min. Every 5 min during the 
incubation the suspension was mixed with a 5 ml pipette. After incubation the tube 
was centrifuged at 300 g for five min and the supernatant carefully removed. The 
pellet was resuspended in 5 ml Dissociation medium 2 and the tube incubated for 
another 30 min at 37 °C. Again, the suspension was triturated every 5 min during the 
incubation. After 5 min centrifugation at 300 g the supernatant was removed carefully 
and the pellet resuspended in 2 ml of Red Blood Cell Lysis Buffer (Roche) and 
incubated 10 min at RT. 5 ml of PBS were added and the suspension centrifuged 
again for 5 min at 300 g. Subsequently the pellet was resuspended in 10 ml PBS and 
the solution filtered over a 70 µm cell strainer (BD Bioscience) into a sterile 50 ml 
tube. Following another round of centrifugation, the cell pellet was resuspended in 10 
ml tumour sphere medium with growth factors. The cells were cultured until there 
were enough spheres to freeze several cryo vials.  
 
6.4.4.2 Cell culture conditions for established cell lines 
 
All glioblastoma cell lines were cultured in DMEM containing 10 % fetal calf serum on 
10 cm tissue culture dishes under adherent conditions. For several experiments  
glioblastoma cell lines were cultured under tumour sphere conditions: to prevent 
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attachment of the cells to the plate surface the cell culture dishes were coated with 
10 mg/ml pHEMA in 95 % ethanol, dried, rinsed with PBS and plated in tumour 
sphere medium supplemented with 20 ng/ml EGF and bFGF. 
HEK 293 cells were cultured in DMEM supplemented with 10 % fetal calf serum on 
tissue culture dishes or flasks.  
 
6.4.4.3 Subculturing cells 
 
Tumour sphere cultures of primary glioblastoma cells were split, depending on their 
size, every 7 to 10 days. The spheres were centrifuged for 3 min at 900 rpm, the 
supernatant discarded and the pellet was incubated with 1 ml of accutase solution at 
37 °C for 15 min. The cell suspension was triturated gently with a 1000 µl pipette tip, 
9 ml tumour sphere medium added and filtered over a 40 µm cell strainer. After 
another round of centrifugation the cells were resuspended in fresh TSM medium 
including growth factors. 
Adherent cells were washed with PBS and covered with 3 ml Trypsin-EDTA solution 
and incubated at 37 °C for 3 min until the cells detached from the plate. Hereafter 
10ml of complete growth medium were added and the cells aspirated by gently 
pipetting. The cell suspension was centrifuged at 1000 rpm for 3 min, the supernatant 
discarded and the cells resuspended in fresh complete growth medium and 
subcultured in ratios between 1:5 and 1:20 depending on the cell line. 
 
6.4.4.4 Cryopreservation of cells 
 
The primary glioblastoma cells should be used at low passage number, as there is a 
risk of genetic alterations and phenotypic shifts over the course of prolonged culture 
with multiple passaging. Therefore, a substantial number of aliquots should be 
cryopreserved at the earliest passage when they can be sufficiently expanded. 
Subsequently, fresh frozen aliquots should be periodically thawed and cultured for a 
limited number of passages and new fresh aliquots at low passages should be 
frozen. 
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For cryopreservation the primary glioblastoma cells were centrifuged for 3 min at 900 
rpm. The pellet of 1 petri dish was resuspended in 2 ml of Cryo-SFM 
cryopreservation medium and distributed to 2 cryo vials, which were placed into a 
commercial available cryo-container (#5100-0001, Thermo) used to control the 
freezing rate of cells. The container was filled with isopropyl alcohol at room 
temperature, which leads to a freezing rate of 1 °C/min when placed at -80 °C. The 
following day the vials were transferred to liquid nitrogen for long-term storage. 
For adherent cells dishes with 70-90% cell confluence were trypsinized, centrifuged 
for 3 min at 1000 rpm and resuspended in 2 ml DMEM, 20 % FCS, 10 % DMSO, 
transferred to 2 cryo vials and frozen as described above. 
Cryopreserved cells were rapidly thawed in a water bath at 37 °C and mixed with 10 
ml of the corresponding culture medium and seeded on the respective culture dishes. 
The following day the medium was changed and, if necessary, replaced with medium 
containing antibiotics for transgene expression or selection. 
 
6.4.4.5 Determining cell number 
 
Cell number was determined using the CASY Cell Counter and Analyzer System 
Model TT (# 05651697001, Roche Diagnostics GmbH), which works via electronic 
pulse area analysis and measures cell number, size distribution and viability of a 
sample. Cell counting was performed by diluting 100µl cell suspension in 10ml CASY 
ton solution (# 05651808001, Roche Diagnostics GmbH) and analysed according to 
the manufacturer’s instructions. 
 
6.4.4.6 Producing lentiviruses in HEK 293T cells using calcium phosphate 
transfection  
 
All steps were carried out in a S2 (biosafety level 2) laboratory. 
Expression Arrest pGIPZ lentiviral shRNA vectors, as well as the pGIPZ non 
silencing control were purchased from Open Biosystems. Viral particles were 
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produced through calcium phosphate co-transfection with lentiviral vector and 
packaging vectors. 
For the calcium phosphate transfection method HEK 293T cells were seeded at a 
density of 4 x 106 cells per T75 tissue culture flask in full medium (DMEM/10 % FCS) 
the day before transfection. The following day a medium change was performed 2 h 
before transfection using 9 ml of serum containing medium. For each transfection 25 
µg specific lentiviral vector, 12.5 μg of ENV plasmid (p-CL2-VSV-G) and 12.5 μg of 
core packaging plasmid (pS-PAX2) were added to 450 μl sterile filtered water in a 50 
ml tube. Additionally 50 μl of 2.5 M CaCl2 were added. DNA was precipitated by 
dropwise addition 500 μl of 2x HBS to the DNA/CaCl2 mixture while vortexing the 
mixture vigorously. After additional vortexing for one min, the mixture was incubated 
at RT for 30 min. In the meantime 10 µl of 10 mM chloroquine stock (final 
concentration 10 μM, #C6628-25g, Sigma) was added to the flask. 1 ml of 
precipitated DNA solution was slowly pipetted into the dish and cells were placed at 
37 °C for up to 16 h. The transfection mixture was aspirated and replaced by 10 ml of 
standard culture medium. The virus containing supernatant was collected 48 and 72 
h post-transfection into a sterile tube, which was stored at 4 °C. Addition of 10 ml 
fresh standard culture medium was carried out by pipetting slowly at the rim of the 
flask as HEK293T cells easily detach. Transfection efficiency could be monitored 
microscopically for expression of EmGFP. 
Before concentrating the virus, the supernatant was filtered through a sterile, 0.45 μm 
low protein binding filter (Millex-HV 0.45 μm PVDF filters, Millipore  #SLHVR25LS) to 
remove any remaining cellular debris. Viral supernatant was pipetted into a sterile 
38.5 ml ultracentrifuge tube (PA thick-walled-UC-tube, Herolab), which was already 
placed in the centrifuge bucket on a balance under the tissue culture hood. Tubes 
were balanced to 0.1 g exactly and ultracentrifugation was performed at 20000 g for 
4 h at 4 °C in a Sorvall Pro 80 Ultracentrifuge and an AH-629 swinging bucket rotor. 
The supernatant was discarded by decanting and residual liquid was removed by 
placing the tube upside down on a beforehand UV-lighted paper for a few min. The 
desired resuspension volume (100 μl-250 μl) of DMEM (no serum) was pipetted at 
the bottom of the tube. In order to dislodge the viral particles from the protein pellet 
the suspension was incubated for 5-10 min at 4 °C and then gently pipetted about 30 
times up and down trying to avoid formation of air bubbles. The resuspended pellet 
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was transferred to a sterile 1.5 ml tube and centrifuged in a microfuge at full speed 
for 5 min at 4 °C. The supernatant was placed in a new, sterile 1,5 ml tube, aliquoted 
into multiple vials at 10-20 μl and stored at -80 °C. Usually the virus production per 
lentiviral vector was performed at least in duplicates and the concentrated virus was 
combined at the end to obtain higher viral titers. 
 
6.4.4.7 Titration of lentiviral particles 
 
For determining the virus titer 2,5 x 104 G55TL cells were seeded in 24 wells and 
titration was performed according to the manufacturer’s directions including the 
addition of 8 µg/ml polybrene (#H9268-5g, Sigma) (Manual: Trans-Lentiviral shRNA 
Bulk Packaging System). Transduced cells were counted as described in the manual 
and transducing units per ml determined using the following formula: 
Number of TurboGFP positive colonies counted x dilution factor x 40 = # TU/ml 
The final TU/ml was obtained by assessing the average from the number of TU/ml of 
the successive dilutions. 
 
6.4.4.8 Lentiviral transduction of cells 
 
All steps were carried out in a S2 (biosafety level 2) laboratory. 
 
6.4.4.8.1 Stable transduction of primary glioblastoma cell lines 
 
Depending on the cell line and desired multiplicity of infection (MOI), primary 
glioblastoma cells were seeded at a density between 5x104 (12-well plate, 400 µl 
total volume including medium, polybrene and virus stock) and 1x106 (6-well plate, 
800 µl total volume including medium, polybrene and virus stock) cells on cell culture 
multiwell plates coated with laminin (Sigma-Aldrich # L2020 solution in PBS (10 
µg/ml), incubated at 37 °C for 3-5 h) in serum free tumour sphere medium without 
antibiotics, containing 8 µg/ml polybrene. 
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Lentiviral particles were added according to the desired MOI and the cells were 
incubated overnight. The following day the cells were washed with PBS and new 
tumor sphere medium was added. Selection was started with the corresponding 
antibiotic two days after transduction. Five days after viral transduction, cells were 
detached from the monolayer on laminin using accutase and seeded as sphere 
cultures in 6-well suspension culture plates in tumour sphere medium. 
 
6.4.4.8.2 Stable transduction of glioblastoma cell lines 
 
Depending on the cell line and desired MOI cells were seeded at a density of 5 x 103 
and 5 x 105 cell per well in a 24-well cell culture plate (600 µl total volume including 
medium, polybrene and virus stock) in DMEM/10 % FCS containing 8 µg/ml 
polybrene. Lentiviral particles were added according to the desired MOI and the cells 
were incubated overnight. The following day cells were washed with PBS and new 
medium was added. In the presence of a selection marker, selection was started with 
the corresponding antibiotic. When the cells reached a confluence of around 80 % 
they were split to larger cell culture dishes. 
 
6.4.4.9 Hypoxic incubation of cells 
 
Before cells were cultured under hypoxic conditions medium was changed in all 
corresponding samples of the experiment to be compared. For hypoxic treatment 
cells were grown at 1 % O2 and 5 % CO2 for the indicated time points in an O2 control 
Hypoxic Workstation (Coy Lab, Grass Lake, USA). 
 
6.4.4.10 Sphere formation assay 
 
For the determination of secondary sphere formation (sphere forming units (SFU)) 
cells were seeded at a density of 1x106 cells on either petri dishes (primary 
glioblastoma cells) or pHEMA coated tissue culture dishes (glioblastoma cell lines) in 
tumour sphere medium for 7 days. The cells were then split to suspension 6-well 
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plates (primary glioblastoma cells, 1000 cells per well) or pHEMA coated 6-well 
tissue culture plates (glioblastoma cell lines, 1000 cells per well) with 6 wells per 
condition. Spheres consisting of 4 or more cells were counted and presented as the 
percentage of sphere forming cells after 7 days. 
 
6.4.4.11 Fluorescence activated cell sorting (FACS) 
 
Cells were seeded 3 days before performing the FACS experiment into 6 well dishes 
(100.000 cells per well). Cells were seeded in six replicates. In addition three 
additional wells were seeded for IgG control, unstained control and GFP control. 
The cells were dissociated with accutase containing 100 U/ml DNase I for 15 min at 
37 °C. Afterwards the cells were cooled down on ice and 9ml staining buffer added 
and the cells were triturated and centrifuged at 4 °C for 3 min at a speed of 900 rpm. 
The supernatant was discarded by inverting the tube and the cells were resuspended 
in 3.5 ml staining buffer. A cell strainer was placed on a FACS tube (# 55.1579, 
Sarstedt) and the cells were passed through it. Again the cells were centrifuged at 4 
°C at 900 rpm for 3 min. The centrifugation was followed by two washing steps. The 
supernatant was discarded by inverting the tube. Approximately 100 µl buffer were 
left in the tube. 20 µl (60 µg) of normal mouse IgG (# 10400C, Invitrogen) was added 
to block unspecific binding. Cells were incubated on ice in the fridge for 20 min. The 
fluorophore-coupled antibody against CD15 (# 642917, BD Horizon) or IgG control (# 
561286, BD Horizon) was added (5 µg/ml) and incubated, protected from light, for 30 
min on ice in the fridge. After the antibody incubation the cells were washed 2 times 
with staining buffer. 
For data acquisition with the BD FACS Canto the first step was to perform the 
compensation measurements and to find the right settings for SSC (side scatter) and 
FSC (forward scatter) and the suitable voltage values to detect the fluorophores. 
Following compensation samples were analysed: non-stained cells, dead cells 
(incubated shortly before measuring with 1 µl of SYTOX red (# S34859, Molecular 
Probes), GFP control (cells were expressing GFP) and compensation beads (# 01-
1111-42, eBioscience) coupled with IgG + used fluorophore. Afterwards the normal 
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samples were analysed, also incubated with SYTOX to detect the dead cell 
population. 
The acquired data was analysed with FlowJo software to gate the dead cell 
populations and the CD15 positive cells. The obtained percentages of populations 
were exported to EXCEL to generate graphs. Dot Plots were exported directly from 
FlowJo V2.2. 
 
6.4.4.12 Modified Boyden Chamber assay 
 
To assess the ability of cells to migrate through filters with defined pore sizes and/or 
to invade through a basement membrane matrix such as matrigel a modified Boyden 
chamber assay was performed. 24 well transwell plates (with 12 polycarbonate 
membrane inserts with a pore size of 8.0 µm; # 3422 Corning/Costar) were used. 
100 µl matrigel (Matrigel # 356234; BD) were mixed with 900 µl TSM (containing 
EGF and FGF). 700 µl of this mixture was used to resuspend a cell pellet of a 
particular cell number (for G55 100.000 cells per well, for 46x 200.000 cells per well). 
For each condition 6 wells were prepared. 100 µl of the matrigel/cells suspension 
was pipetted carefully onto the filter in the upper compartment of the insert. The plate 
was incubated for 1h at 37 °C to allow polymerization of the matrigel. Afterwards 600 
µl of TSM containing EGF/FGF and 1 % FCS were added to the lower compartment 
of the well and 100 µl of TSM containing only EGF/FGF were added to the upper 
compartment on top of the matrigel. After 18 h incubation at 37 °C the cells were 
fixed for 10 min by replacing the medium of the lower compartment with 70 % 
ethanol. The cells were rehydrated by a washing step with 1x PBS and the nuclei of 
the cells were stained with DAPI (1:5000 in 1x PBS; 10 min incubation). After one last 
washing step with 1x PBS pictures of the DAPI signal of the upper compartment were 
taken with a fluorescence microscope using the 2.5x objective (LEICA BM IL LED, 
camera: LEICA DFC420C). 1 picture of the whole compartment was taken. 
Afterwards the upper side of the filter was cleaned with a q-tip to remove all cells. 
The filter of the insert was removed and mounted with the lower side facing upwards 
to microscope slides with fluorescence mounting medium (Dako). After drying the 
slides over night at room temperature pictures were taken of the filters as described 
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above. The amount of cells was analysed with the program ImageJ 
(http://imagej.nih.gov/ij/). The number of cells that had moved through the filter was 
divided by the number of cells in the upper compartment and later on normalized to 
the control cells.  
 
 6.4.4.13 Collagen Invasion assay 
 
To assess the invasion ability of a tumour sphere a collagen invasion assay was 
performed. 
A 12 well plate was coated with 300 µl per well of the collagen solution and incubated 
for 30 min at 37 °C to allow polymerisation of the collagen. 48-72 h old single tumour 
spheres were picked with a 10 µl pipet tip and placed in the middle of the well. The 
spheres were covered with 360 µl of the collagen solution and again incubated for 
30min for polymerisation. Subsequently pictures of the spheres were taken with a 
light microscope to record the size of the spheres at time point 0. Afterwards every 24 
h pictures were taken to document the invasion of the spheres. The last time point 
was reached after 96 h. The invasion of the spheres was analysed with the 
programmes Adobe Photoshop and ImageJ. The invasion was calculated with the 
formula of the Invasion Index (Perimeter)2/Area  
 
6.4.5 In vivo tumour models 
6.4.5.1 Intracranial tumour xenograft models 
 
For intracranial tumour xenograft transplantations mice were anesthetized (through 
intraperitoneal injection of 150 µl/20 g bodyweight of 2 ml 10 % ketamine, 0.5 ml 2 % 
xylazine in 9 ml 0.9 % saline) and placed into a stereotactic apparatus (Kopf 
Instruments). The scalp was disinfected with a swab dipped in 70% ethanol and 
opened with a type 15 scalpel. A burr hole was made 2mm left of the sagittal suture 
and 0.5 mm anterior to the bregma using a micro drill 0.7 mm in diameter. The cells, 
resuspended in cold CO2 independent medium, were slowly implanted at a depth of 3 
mm from the dura using a 2.5 µl Hamilton syringe equipped with an unbeveled 33G 
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needle. The mice were kept until the development of neurological symptoms and, in 
case of comparative experiments, sacrificed at the same time point. 
Cell lines used for intracranial tumour implantations: G55 nsc (5000 cells in 1µl), 
G55shSnail/shSlug (5000 cells in 1 µl), 46x nsc (200.000 cell in 2 µl), 46x 
shSnail/shSlug (200.000 cells in 2 µl) 
 
6.4.5.2 Perfusion and tissue preparation 
 
Intracranial tumor bearing mice were anesthetized (through intraperitoneal injection 
of 250 µl/20 g bodyweight of 2ml 10% ketamine, 1 ml 2 % xylazine in 9 ml 0.9 % 
saline) the chest was opened and vascular perfusion was performed using 0.9% 
saline for 3 min and 4 % PFA as a fixative for 6 min via a 13 gauge needle inserted 
through the left ventricle. The brains were dissected and additionally fixed in 4 % PFA 
at 4 °C over night. The brains were dehydrated in 30 % sucrose for about 4 days at 4 
°C and subsequently rapidly frozen on dry ice for sectioning with a sliding microtome 
(Leica # SM2010R). The whole brain was sectioned by collecting 10 x 40 µm 
sections followed by 4 x 20 µm sections in 14 sequential microcentrifuge tubes 
containing cryoprotection solution. When the last section was stored in the tube, 
collection of sections was performed in the first tube again, resulting in brain sections 
of a 480 µm interval in every microcentrifuge tube. The sections were stored at -20 
°C. 
 
6.4.5.3 Quantification of tumour volume and hematoxylin an eosin (HE) staining 
 
The tumour volume of intracranial tumours was quantified on HE stainings. 
The hematoxylin solution (# A4840-500, Applichem) consists of an oxidizing agent, 
most commonly sodium iodide that converts hematoxylin to hematein and a mordent 
usually aluminium or iron compounds. The hematoxylin-metal complex acts as a 
basic dye, staining nucleic acids in the nucleus and cytoplasm blue. On the contrary 
eosin (1% eosin in 70 % EtOH, add 1 drop of concentrated acetic acid per 100 ml), 
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acting as an alcohol-based acidic dye, stains more basic proteins within the 
cytoplasm pink. 
A series of brain sections covering the whole brain in 480 µm intervals was mounted 
on microscope slides and dried at room temperature overnight. The slides were fit 
into a removable glass slide rack and rehydrated in PBS for two min followed by a 
rinse in ultrapure aqua dest. Hematoxylin staining was performed for 8-10 min in a 
staining jar. The slides were rinsed in ultrapure aqua dest. and blued in tap water for 
2 min, followed by an additional rinse in ultrapure aqua dest. Cytoplasmic eosin 
staining was performed for 6 min followed by dehydration in an ascending alcohol 
series (2 times 70 % and 96 % ethanol for 30 s and 2 times for 5 min in 100 % 
ethanol). Finally the slides were transferred to xylol 2 times for 5 min each and 
subsequently mounted with Cytoseal™ XYL (Richard-Allen Scientific) and dried 
under the chemical fume hood. 
The tumour volume was calculated by tracing the tumour area using the semi-
automated stereological system Stereo Investigator 4.34 (MicroBrightField Inc.) or 
ImageJ and calculating the volume with the following formula: 
V [mm3] = total tumour area [mm2] x12 x 0.04 mm (thickness of sections) 
 
6.4.5.4 Analysis of invasiveness of xenograft tumours 
 
The invasive area of the xenograft tumours was analyses with the help of the GFP 
signal of the injected cells. 10 pictures of the tumour rim and the invasive area per 
tumour were taken with a fluorescence microscope (LEICA TCS SPE, camera: 
LEICA DFC420C; 20x objective). With the program ImageJ the length of the tumour 
rim and the area of the invading tumour cells was measured. The ratio of the invasive 
front to the initial perimeter of the tumour rim was calculated with the formula area of 
the invasive front / length of the tumour rim. 
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6.4.6 Immunofluorescence stainings 
6.4.6.1 BrdU labelling and staining of cells 
 
5-bromo-2-deoxy-uridine (BrdU) is a synthetic nucleoside and analogue of thymidine 
that can be incorporated into DNA during DNA synthesis. By using monoclonal 
antibodies directed against BrdU and enzyme- or fluorochrome-conjugated 
secondary antibodies, cell proliferation can be assessed. 
Cells were cultured as spheres in TSM medium. For each condition triplets were 
prepared. The cells were separated with accutase and washed with 1x PBS. BrdU 
was added to the cells to a final concentration of 10 µm and incubated for 10 min at 
37 °C. In parallel a control without BrdU treatment was prepared. After the incubation 
the cells were put directly on ice and 100000 cells transferred on microscope slides 
using a cytospin centrifuge (Sakura Finetek) (800 rpm, 3min). The cells on the 
microscope slides were fixed with 4 % PFA for 30 min at 4 °C followed by a short 
rinse in 1x PBS. Afterwards antigen retrieval was performed by boiling the slides for 5 
min in 0.01 M sodium citrate buffer (1.47 g tri sodium citrate in 500 ml H2O, adjust pH 
with 1 M HCl), pH 6.0 (before boiling the slides preheat the buffer for 20 min). The 
slides were cooled down in the buffer for 15min at room temperature followed by 3 
washing steps of 2 min each in 1x PBS. After the washing steps the slides were 
incubated for 30 min in 2 N HCl to denature the BrdU-labelled DNA in the nucleus 
and make it accessible for antibody binding. Afterwards the slides were immersed 2 
times for 5 min in 0.1 M borate buffer (3.8 g di-sodium tetra borate decahydrate in 
100ml H2O), pH 8.5  to neutralize the acid from the step before. Again the slides were 
washed 3 times 2 min in 1x PBS. For 1h the slides were blocked with 20 % normal 
goat serum/1xPBS. The primary anti-BrdU antibody (1:200 in 10% normal goat 
serum/1x PBS) was incubated over night at 4 °C. The next day the slides were 
washed 3 times 5 min with 1x PBS followed by incubation with the Alexa-568 
secondary antibody (1:500 in 10 % normal goat serum/PBS) for 1 h at room 
temperature. Afterwards the cells were counterstained with DAPI (1:5000 in 1x PBS) 
to visualize the nuclei. Again the slides were washed with 1x PBS 3 times for 2 min. 
The cells were mounted with Dako Fluorescence mounting medium. The proliferation 
was analysed as a percentage of BrdU positive cells in 5 randomly selected 20x 
fields per slide (3 replicates per condition). 
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6.4.6.2 Free-floating endomucin staining of 40µm brain sections 
 
Endomucin (endothelial sialomucin) is a protein expressed on endothelial cells. To 
analyse the vasculature of xenograft tumours a monoclonal anti-mouse Endomucin 
antibody was used. 
The 40 µm brain sections were put in a 24-well plate (per well maximum 3 sections) 
and permeabilized for 1 h in 1 % Triton X-100/1x PBS at room temperature while 
shaking on an orbital shaker. Afterwards the sections were blocked with 0.5 % Triton 
X-100/1x PBS/5 % normal goat serum at room temperature. The primary endomucin 
antibody (1:500 in blocking buffer (20% normal goat serum/1x PBS/0.01 % Triton X-
100)) was added to the sections and incubated for two night at 4 °C while shaking on 
an orbital shaker. 
After the incubation with the primary antibody the sections were washed 3 times for 
15 min in 1x PBS/0.01 % Triton X-100 and once with 1x PBS for 15 min. The 
secondary antibody (goat anti rat Alexa Fluor 568, 1:200 in blocking buffer) was 
added and incubated over night at 4 °C. The next day the sections were washed 3 
times for 15 min with 1x PBS/0.01 % Triton X-100, followed by one washing step with 
1x PBS for 15 min. The sections were counterstained with DAPI (1:5000 in 1x PBS) 
to visualize the nuclei. Afterwards, the sections were washed again 2 times for 5 min 
with 1x PBS and mounted with fluorescence mounting medium (#S3023 Dako). 
The vessel area was analysed as percentage of the total tumour area in 10 pictures 
per tumour. 
 
6.4.6.3 Phospho-histone 3 staining of 40µm brain sections 
 
To assess the proliferation of tumour cells in xenografts a staining of phospho-
histone 3 was performed. 
The brain sections were mounted on microscope slides and dried over night at room 
temperature. The sections were encircled with Cytomation pen (#S2002). Sections 
were boiled in TE buffer for 5 min, the slides were cooled down for 20 min at room 
temperature. Afterwards the sections were washed 2 times 5 min in 1x PBS/0.01 % 
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Triton X-100 followed by one washing step in 1x PBS. To permeabilise the sections 
they were incubated for 4 h at room temperature in blocking buffer. The primary 
antibody against human-phospho Histone 3 was diluted 1:200 in incubation buffer 
(10% normal goat serum/1xPBS/0.01% TritonX-100) and the slices were incubated 
for two nights at 4°C in a humidified chamber. 
After the incubation with the primary antibody the slices were washed in 1x PBS/0.01 
% Triton X-100 several h (changed 2 times). The rest of the day the slices were 
washed in 1x PBS. The secondary antibody was diluted in 1:500 in incubation buffer 
and the slices were incubated over night at room temperature in a humidified 
chamber. The next day the slices were washed several h in 1x PBS/0.01 % Triton X-
100 (two changes) followed by washing once in 1x PBS for the rest of the day. The 
slices were counterstained with DAPI (1:5000 in PBS) to visualize the nuclei. 
Afterwards the slices were washed again 3 times 5min in PBS and then mounted with 
fluorescence mounting medium (#S3023 Dako). The amount of proliferating cells was 
analysed by taking 10 pictures per slice with a 10x objective and calculating the 
number of phospho-histone 3 positive cells per mm2.  
 
6.4.6.4 Staining of apoptotic cells 
 
To stain apoptotic cells in vitro and in vivo the apoptosis detection kit ApopTag Red in 
situ from Millipore was used. This kit is based on the TUNEL assay and detects 
double- and single-stranded DNA breaks by labelling the free 3’OH ends of the 
damaged DNA with fluorescent nucleotides. The procedure was performed according 
to the manual of the manufacturer. 
 
6.4.7 Statistical analysis  
 
Results are presented as mean + standard error of mean. Statistical comparisons of 
values were made using the Student’s t-test or Mann-Whitney U-test. Statistical 
significance was assumed at p < 0.05 *, p < 0.01 **, p < 0.001 ***. 
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° C:   degree Celsius 
µg:   microgram 
µl:   microlitre 
µm:  micrometre 
A2B5:  antigen 
ADAM:  a disintegrin and metalloproteinase 
APS:   ammoniumpersulfate 
ASPHD2:  aspartate beta-hydroxylase domain containing 2 
BMP7:  bone morphogenic protein 7 
BrdU:   bromodeoxyuridine 
BTSC:  brain tumour stem cell 
C/EBP-β/ δ: CAAT enhancer binding protein 
CD133: prominin 1 glycoprotein 
CD15:  3-fucosyl-N-acetyl-lactosamine antigen cluster 
CD24:  cluster of differentiation 24 antigen 
CD44:  cell surface glycoprotein 
CDKN2A:  cyclin-dependent kinase inhibitor 2A 
CNS:   central nervous system 
Co:   control 
coREST:  co-repressor of REST (RE1-Silencing Transcription factor) 
CPS:   cryo-protection solution 
CRISPR/Cas9: clustered regularly interspaced short palindromic repeats/caspase 9 
CSC:   cancer stem cell 
CXCR4:  CXC-motif chemokine receptor 4 
DAPI:  4′,6-Diamidin-2-phenylindol 
DEPC:  di-ethylpyrocarbonate 
DKFZ:  Deutsches Krebsforschungszentrum 
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DLL3:  Notch ligand delta like 3 
DNA:   deoxyribonucleic acid 
E-cadherin:  epithelial cadherin 
ECM:   extracellular matrix 
EGF:   epidermal growth factor 
EGFR:  epidermal growth factor receptor 
EMT:   epithelial to mesenchymal transition 
FACS:  fluorescence activated cell sorting 
FBXL14:  F-box protein 14 
FCS:   fetal calf serum 
FGF:   fibroblast growth factor 
g:   gram 
G34:   glycine 34 
GABA:  gamma-aminobutyric acid 
GABRA1:  gamma-aminobutyric acid receptor A 1 
GBM:   glioblastoma multiforme 
G-CIMP:  CpG-island methylator phenotype 
GFP/eGFP:  (enhanced) green fluorescence protein 
GMT:   glial to mesenchymal transition 
GSK3β:  glycogen synthase kinase 3 beta 
h:   hour 
H&E:   haematoxylin and eosin 
H3F3A:  histone 3 family 3A 
HBS:   HEPES buffered saline  
HDAC:  histone deacetylase 
HEY1:  Hes-related family BHLH transcription factor with YRPW motif 1 
HGF:   hepatocyte growth factor 
HIF:   hypoxia inducible factor 
Id1:   DNA-binding protein inhibitor 
IDH1:  isocitrate dehydrogenase 
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IgG:   immunoglobulin G 
IKKα:   IκB (inhibitor of kappa B) kinase α 
IL:   interleukin 
JNK:   c-Jun N-terminal kinase 
K27:   lysine 27 
l:   litre 
LB:   Luria-Bertani 
LOX:  lysyl oxidase 
LSD:   lysine specific demethylase 
LTBP:  latent TGFβ-binding proteins 
M:   molar 
MAML3:  mastermind-like protein 3 
MAP2:  microtubule associated protein 2 
Mes:   mesenchymal 
mg:   milligram   
min:   minute 
miRNA:  micro ribonucleic acid 
ml:   milliltre  
mm:   millimetre 
mM:   millimolar 
MMP:  matrix metalloproteinase 
MOI:   multiplicity of infection 
MRI:   magnetic resonance imaging 
mRNA:  messenger ribonucleic acid 
N-cadherin: neural cadherin 
NCAM:  neural cell adhesion molecule 1 
NEFL:  neurofilament, light polypeptide 
NES:   nuclear export sequence 
NF1:   neurofibromin 1 
NFATc2:  nuclear factor of activated T cells 2 
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NF-κB:  nuclear factor kappa B 
ng:   nanogram 
nm:   nanometre 
Oct4:   octamer-binding transcription factor 4 
Olig2:  oligodendroglial marker 2 
p53 or TP53: cellular tumour antigen p53 
PAK1:  p21 activated kinase 1 
PB:   phosphate buffer 
PBS:   phosphate buffered saline 
PCAM1:  Platelet endothelial cell adhesion molecule 
PCNA:  proliferating cell nuclear antigen 
PCR:   polymerase chain reaction 
PDGF:  platelet derived growth factor 
PDGFRA:  platelet derived growth factor receptor A 
PFA:   paraformaldehyde 
PI3K-Akt:  Phosphatidylinositol 3-kinase-Akt pathway 
PKD1  polycystin 1 
PN:   proneural 
PRC2:  polycomb repressor complex 2 
PRMT5:  protein Arginine Methyltransferase 5 
Prolif:   proliferative 
PTEN: phosphatase and tensin homologue 
q-RT PCR:  quantitative real time polymerase chain reaction 
Ras/ERK:  rat sarcoma G-protein/Extracellular Signal-regulated Kinase-1 pathway 
RAS-MAPK: rat sarcoma G-protein/ Mitogen-activated protein kinases 
RB:   retinoblastoma protein 
RNA:   ribonucleic acid 
RT:   room temperature 
RTK:   receptor tyrosine kinase 
sec:   second 
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Ser-10:  serine 10 
SFU:   sphere forming units 
shRNA:  short hairpin ribonucleic acid 
SLC12A5: potassium/chloride transporter 
SNAG:  Snail/Gfi domain 
Sox2:   sex determining region Y-box 2 
SRD:   serine rich domain 
STAT3:  signal transducer and activator of transcription 3 
SVZ:   subventricular zome 
SYT1:  synaptotagmin I 
TCGA:  The Cancer Genome Atlas 
TGFβ1:  transforming growth factor β1  
TNFα:  tumour necrosis factor alpha 
TOP2A:  topoisomerase 2A 
TU:   transducing units 
TUNEL:  TdT mediated dUTP-biotin nick end labelling 
uPA:   urokinase-type plasminogene activator 
uPAR:  urokinase-type plasminogene activator receptor 
VEGF:  vascular endothelial growth factor 
VHL:   von Hippel-Lindau 
WHO:  world health organisation 
Wnt:   wingless gene from drosophila melanogaster 
YKL40:  human chitinase 3 like 
ZEB:   Zinc finger E-box binding homeobox 1 
β-TrCP:  beta-transducin repeat containing protein 
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